[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 707
1. Hindle AG, Lawler JM, Campbell KL, Horning M: Muscle senescence in short-lived wild mammals, the soricine shrews Blarina brevicauda and Sorex palustris. J Exp Zool A Ecol Genet Physiol; 2009 Jun 1;311(5):358-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed the emerging pattern of skeletal muscle senescence (contractile/connective tissue components) in sympatric species, the semi-aquatic water shrew (WS), Sorex palustris, and the terrestrial short-tailed shrew (STS), Blarina brevicauda, to determine if muscle aging occurs in wild, short-lived mammals (H(0): shrews do not survive to an age where senescence occurs), and if so, whether these alterations are species-specific.
  • The area ratio of muscle:collagen decreased with age in both species, but was considerably lower in adult STS, suggesting species-specificity of senescence.
  • Though juvenile interspecific comparisons revealed no significance, adult WS myocytes had 68% larger cross-sectional area and occurred at 28% lower fibers/area than those of adult STS.
  • Our findings moreover illustrate that differential age adjustments in contractile/connective tissue components of muscle occur in the two species of wild-caught shrews.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19296507.001).
  • [ISSN] 1932-5223
  • [Journal-full-title] Journal of experimental zoology. Part A, Ecological genetics and physiology
  • [ISO-abbreviation] J Exp Zool A Ecol Genet Physiol
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R03 AR054084; United States / NIAMS NIH HHS / AR / AR054084
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen
  • [Other-IDs] NLM/ NIHMS700152; NLM/ PMC4487982
  •  go-up   go-down


2. Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, Vordermark D: Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer; 2010;10:132
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients.
  • However, only a few studies investigated the prognostic impact of expression of OPN in soft tissue sarcomas (STS) yet.
  • METHODS: This study is based on tumor and serum samples from 93 adult STS patients.
  • We investigated OPN protein levels in serum (n = 86) and tumor tissue (n = 80) by ELISA and OPN mRNA levels in tumor tissue (n = 68) by quantitative real-time PCR.
  • RESULTS: No correlation was found between OPN levels in serum and tumor tissue.
  • OPN protein levels in the tumor tissue were associated with higher stage (p = 0.06), higher grade (p = 0.003), subtype (p = 0.07) and an increased rate of relapse (p = 0.02).
  • In addition, using a Cox's proportional hazards regression model, we found that an elevated OPN protein level in the serum and tumor tissue extracts is a significant negative prognostic factor for patients with STS.
  • CONCLUSION: Our data suggest OPN protein in serum as well as in tumor tissue extracts is an important prognostic factor for soft tissue sarcoma patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Osteopontin / metabolism. Sarcoma / metabolism. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Hypoxia / physiology. Humans. Middle Aged. Neoplasm Staging. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3419-27 [17896150.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7170-4 [17525744.001]
  • [Cites] Cell Mol Biol Lett. 2008;13(1):11-9 [17952379.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):103-18 [18049863.001]
  • [Cites] Curr Med Chem. 2008;15(4):322-38 [18288988.001]
  • [Cites] Head Neck. 2008 Jun;30(6):776-81 [18228527.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Aug;134(8):909-17 [18210151.001]
  • [Cites] Lab Invest. 2008 Dec;88(12):1264-77 [18838962.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6B):4105-10 [19192668.001]
  • [Cites] J Cell Physiol. 2000 Jul;184(1):118-30 [10825241.001]
  • [Cites] Cancer Lett. 2001 Sep 20;170(2):199-205 [11463499.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):668-74 [11764388.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] Curr Mol Med. 2001 Nov;1(5):621-32 [11899236.001]
  • [Cites] Lancet. 2002 Mar 16;359(9310):943-5 [11918915.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3417-27 [12067984.001]
  • [Cites] Virchows Arch. 2002 Oct;441(4):345-9 [12404059.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1098-104 [12631613.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1588-96 [15014008.001]
  • [Cites] Eur J Cancer. 1993;29A(15):2089-93 [8297645.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):453-7 [16091764.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):740-6 [15970685.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8019-27 [16299231.001]
  • [Cites] Cancer Biol Ther. 2005 Dec;4(12):1336-41 [16258259.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2192-202 [16288209.001]
  • [Cites] BMC Cancer. 2006;6:207 [16911785.001]
  • [Cites] BMC Cancer. 2006;6:237 [17022822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1481-7 [17056190.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):81-90 [17150036.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):98-102 [16675104.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Feb;292(2):C919-26 [17005603.001]
  • [Cites] Radiother Oncol. 2007 Jun;83(3):389-97 [17499868.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6361-71 [17452979.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):889-97 [17960616.001]
  • (PMID = 20377868.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2856551
  •  go-up   go-down


3. Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y, Yamashita T, Chuman H, Beppu Y, Tani Y, Hasegawa T: Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer; 2005 May 1;103(9):1881-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.
  • BACKGROUND: Little is known about the expression of receptor tyrosine kinases in adult soft tissue sarcomas (STS).
  • In the current study, the authors analyzed the expression of epidermal growth factor receptor (EGFR), ERBB2, and KIT in 281 patients with STS who were treated in a single institution.
  • METHODS: The current study included 281 adult patients with STS of the extremity and trunk who were diagnosed and treated in the National Cancer Center, Tokyo.
  • Expression was assessed using immunohistochemical stains for EGFR, ERBB2, and KIT on formalin-fixed, paraffin-embedded tissue sections by standard avidin-biotin peroxidase complex technique and EGFR detection system.
  • CONCLUSIONS: EGFR overexpression was found to be a negative prognostic factor of adult STS, which is strongly associated with histologic grade.
  • STS patients with EGFR overexpression may benefit from treatment with currently available biospecific inhibitors for EGFR.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Sarcoma / metabolism
  • [MeSH-minor] Adult. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Paraffin Embedding. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15772959.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


Advertisement
4. Polsky D, Mastorides S, Kim D, Dudas M, Leon L, Leung D, Woodruff JM, Brennan MF, Osman I, Cordon-Cardo C: Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior. Histol Histopathol; 2006 07;21(7):743-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior.
  • In this study, we examined adult soft tissue sarcomas (ASTS) to determine if alterations of pRB were associated with distinct patterns of pRB expression and clinical outcome.
  • CONCLUSIONS: Inactivation of pRB is common in adult STS, which may be due to either gene loss or post-translational modification, namely hyper-phosphorylation.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Retinoblastoma Protein / metabolism. Sarcoma / metabolism. Soft Tissue Neoplasms / metabolism

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598673.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Retinoblastoma Protein
  •  go-up   go-down


5. Geva R, Jiveliouk I, Inbar M, Meller I, Friedman E, Merimsky O: The co-occurrence of breast cancer and soft tissue sarcoma in a single cohort series. Am J Clin Oncol; 2009 Feb;32(1):34-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The co-occurrence of breast cancer and soft tissue sarcoma in a single cohort series.
  • BACKGROUND: The incidence of breast cancer (BC) and soft tissue sarcoma (STS) in the Israeli general population is 97/10 women and 1.5/10 persons.
  • It is expected that 1.5/10 x 49/10 of the women in the general population will have both BC and STS.
  • METHODS: A retrospective search of 1350 adult STS patient files that were recorded between 1995 and 2005.
  • RESULTS: One hundred thirty-four patients with STS had multiple primary malignancies.
  • BC was observed in 27/64 patients (42%) before/after the STS: BC-first in 19/27, BC-later in 8/27.
  • Of 19 with BC-first the STS was related to radiotherapy in 2, and to lymphedema in 1.
  • Of 8 STS-first, only 1 got chemotherapy before BC.
  • The incidence of BC among all patients with STS-first followed by a second malignancy is 8/58 (14%), or 27/890 (3%) of all women STS-patients in the registry.
  • The incidence of STS among the BC patients was low, and most of our cases were therapy unrelated.
  • Median survival for BC-first was 305 months, versus 213 for STS-first.
  • CONCLUSIONS: BC and STS may naturally occur in the same individual.
  • Practically, BC screening in patients with STS is warranted.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Medullary / pathology. Neoplasms, Second Primary / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Follow-Up Studies. Humans. Incidence. Middle Aged. Retrospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194122.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Grossman ED, Battelli L, Pascual-Leone A: Repetitive TMS over posterior STS disrupts perception of biological motion. Vision Res; 2005 Oct;45(22):2847-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repetitive TMS over posterior STS disrupts perception of biological motion.
  • In connection with previous brain imaging results, our findings demonstrate that normal functioning of the posterior STS is required for intact perception of biological motion.
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Male. Transcranial Magnetic Stimulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039692.001).
  • [ISSN] 0042-6989
  • [Journal-full-title] Vision research
  • [ISO-abbreviation] Vision Res.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY09258; United States / NEI NIH HHS / EY / EY15960; United States / NCRR NIH HHS / RR / K24 RR018875; United States / NCRR NIH HHS / RR / M01 RR01032; United States / NEI NIH HHS / EY / R01-EY12091
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


7. Bramwell V: When to consider adjuvant/neoadjuvant therapy for adult soft-tissue sarcoma. Oncology (Williston Park); 2007 Apr;21(4):511-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When to consider adjuvant/neoadjuvant therapy for adult soft-tissue sarcoma.
  • In patients with adult soft-tissue sarcoma (ASTS), the use and timing of adjuvant chemotherapy or chemoradiotherapy remains controversial.
  • [MeSH-major] Neoadjuvant Therapy. Neoplasm Recurrence, Local. Sarcoma / drug therapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Meta-Analysis as Topic. Randomized Controlled Trials as Topic. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474349.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  •  go-up   go-down


8. Jain A, Sajeevan KV, Babu KG, Lakshmaiah KC: Chemotherapy in adult soft tissue sarcoma. Indian J Cancer; 2009 Oct-Dec;46(4):274-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in adult soft tissue sarcoma.
  • Soft tissue sarcomas (STSs) are rare and histologically diverse neoplasms.
  • Recent results of various meta-analyses and development of newer drugs have changed the medical management of soft tissue sarcoma.
  • We have carried out an extensive search in PubMed, Medline for almost all relevant articles concerning chemotherapy of soft tissue sarcoma.
  • Newer methodologies such as, Bayesian adaptive randomization and inclusion of newer end points like progression-free rate, time of progression rate, and tumor growth rate will improve the results of sarcoma trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoadjuvant Therapy


9. Fiore M, Casali PG, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C, Gronchi A: Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. Ann Surg Oncol; 2006 Jan;13(1):110-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity.
  • BACKGROUND: We explored the outcome of patients with primary adult soft tissue sarcoma (STS) of the extremities undergoing re-excision after previous unplanned surgery.
  • METHODS: A total of 597 consecutive adult patients with primary extremity STS were treated with conservative surgery at our institution over a 20-year time span.
  • The assessed end points were sarcoma-specific mortality, local recurrence, and distant metastasis.
  • CONCLUSIONS: At a referral center with a liberal policy of re-excisions in adult primary STS of the extremities, the outcome of patients who underwent re-excision was similar to that of patients who had primary resections.
  • [MeSH-major] Neoplasm, Residual / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Extremities. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Regression Analysis. Reoperation. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372156.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Abraham JA, Baldini EH, Butrynski JE: Management of adult soft-tissue sarcoma of the extremities and trunk. Expert Rev Anticancer Ther; 2010 Feb;10(2):233-48
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adult soft-tissue sarcoma of the extremities and trunk.
  • Soft-tissue sarcomas are a heterogeneous group of tumors consisting of approximately 100 distinct diagnoses.
  • [MeSH-major] Sarcoma / surgery
  • [MeSH-minor] Adult. Extremities. Humans. Neoplasm Metastasis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20131999.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Lordick F: [Multidisciplinary treatment for adult soft tissue sarcoma]. Chirurg; 2009 Mar;80(3):209-15
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multidisciplinary treatment for adult soft tissue sarcoma].
  • The current standard in local treatment of soft tissue sarcomas has shifted from amputation and similar mutilating resections to more organ- and function-preserving surgery.
  • Progress may occur when the pathogenesis and molecular profile of specific sarcoma subtypes are better understood, allowing more effective new drugs.
  • Presently the most effective measure to improve the prognosis with soft tissue sarcomas is early patient referral to expert centres, where diagnostic workup and therapy decisions are made on a multidisciplinary basis and updated according to the newest guidelines and study results.
  • [MeSH-major] Patient Care Team. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Child. Combined Modality Therapy. Cooperative Behavior. Disease-Free Survival. Humans. Interdisciplinary Communication. Neoadjuvant Therapy. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1997 Mar;33(3):357-61 [9155517.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1159-62 [9426338.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1706-12 [16134177.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):11-2 [16330666.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):791-6 [11821462.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1061-8 [15930042.001]
  • [Cites] Ann Oncol. 2008 Sep;19 Suppl 7:vii166-9 [18790941.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jan;42(1):64-73 [14752797.001]
  • [Cites] J Clin Oncol. 2007 Mar 10;25(8):1003-8 [17350950.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2717-25 [18451237.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):307-15 [14760127.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2755-63 [17602081.001]
  • [Cites] J Am Acad Dermatol. 2008 Aug;59(2 Suppl 1):S7-9 [18625396.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):429-37 [12850194.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1818-29 [11251014.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2002 Jan;14(1):18-28 [11977013.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):64-9 [12504660.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):612-20 [14745880.001]
  • [Cites] Chirurg. 2008 Jul;79(7):630-7 [18548219.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):565-7 [17613417.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Sep;8(6):536-44 [18781899.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2433-6 [18771914.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):501-6 [17290057.001]
  • [Cites] BMJ. 1998 Jul 11;317(7151):93-4 [9657781.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1195-203 [16505440.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1120-6 [12209699.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3481-7 [9396401.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii89-93 [18456783.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5269-74 [18809609.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Apr;5(2):283-94 [15877525.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3714-5; author reply 3715 [16877745.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • (PMID = 19156392.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


12. Ferron G, Aziza R, Delannes M, Filleron T, Marquès B, Labarre D, Labarre D, Chevreau C: Detection of local recurrences of limb soft-tissue sarcomas: Is magnetic resonance imaging (MRI) relevant? J Clin Oncol; 2009 May 20;27(15_suppl):10582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of local recurrences of limb soft-tissue sarcomas: Is magnetic resonance imaging (MRI) relevant?
  • : 10582 Background: The role of systematic magnetic resonance imaging (MRI) surveillance after resection of soft-tissue sarcomas (STS) of the limb is opened to debate.
  • The aim of our study was to retrospectively evaluate the effectiveness of a MRI surveillance schedule performed in adult patients.
  • METHODS: 124 adult patients have been treated from 1996 to 2006 for a non-metastatic limb STS at our centre: 86 patients (70%) had clear resection margins (R0) and 111 patients (90%) received an adjuvant radiotherapy.
  • CONCLUSIONS: As observed in our study, systematic MRI surveillance is not relevant for the follow-up of all limb soft-tissue sarcomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Italiano A, Delva F, Brouste V, Terrier P, Trassard M, Michels J, Collin F, Coindre J, Blay J, Bui B: Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: A multivariate analysis of the French Sarcoma Group database. J Clin Oncol; 2009 May 20;27(15_suppl):10504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: A multivariate analysis of the French Sarcoma Group database.
  • : 10504 Background: The SMAC meta-analysis failed to demonstrate that adjuvant chemotherapy (AC) significantly improves overall survival (OS) in adult patients with localised resectable soft-tissue sarcoma (STS).
  • We report here the analysis of the impact of AC in the population of STS patients included in the prospective database of the French Sarcoma Group.
  • METHODS: Between 1980 and 1999, 2,029 pts with STS were admitted to one of the 20 tertiary cancer centers of the GSF for the management of a first tumoral event and were included prospectively in a comprehensive database.
  • The commonest pathological subtypes were MFH 22.5%, liposarcoma 18%, leiomyosarcoma 13%, and synovial sarcoma 10%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Dileo P, Bertulli R, Piovesan C, Marrari A, Puma E, Spreafico C, Gronchi A, Olmi P, Gandola L, Casali PG: Long-term results with combined treatment in adult localized extraskeletal Ewing's sarcoma (ES): A retrospective analysis of 51 patients (pts) from a single referral center. J Clin Oncol; 2009 May 20;27(15_suppl):10548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results with combined treatment in adult localized extraskeletal Ewing's sarcoma (ES): A retrospective analysis of 51 patients (pts) from a single referral center.
  • : 10548 Background: After the first description in 1975, only small series of adult extraskeletal ES have been reported.
  • METHODS: We retrospectively reviewed adult pts with extraskeletal, localized ES, undergoing medical therapy between 1988 and 2004, who were included in the dataset of the current Adult Sarcoma Medical Unit at Istituto Nazionale Tumori, Milano, Italy, which serves as a reference center for adult soft tissue sarcoma.
  • CONCLUSIONS: In this series of adult pts with extraskeletal ES, response rate and DFS were comparable to those of ES of bone in conventional series.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963955.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Qiu MZ, Xu F, Wang SS, Luo HY, Wang F, Li FH, Sun XF, Xu GC, Lin TY, Huang HQ, Jiang WQ, Guan ZZ, Xu RH: [Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. Ai Zheng; 2007 Dec;26(12):1344-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
  • BACKGROUND & OBJECTIVE: The response of adult soft tissue sarcoma (STS) to chemotherapy is uncertain.
  • This study was to evaluate the role of chemotherapy in treating adult soft tissue sarcoma.
  • METHODS: Clinical data of 109 adult soft tissue sarcoma patients, treated with chemotherapy at Cancer Center of Sun Yat-sen University from Jan.
  • CONCLUSIONS: MAID and CYVADIC are two effective chemotherapy regimens for adult soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Extremities. Pelvic Neoplasms / drug therapy. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Mesna / therapeutic use. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Palliative Care. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076798.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; CYVADIC protocol; MAID protocol
  •  go-up   go-down


16. Tunn PU, Kettelhack C, Dürr HR: Standardized approach to the treatment of adult soft tissue sarcoma of the extremities. Recent Results Cancer Res; 2009;179:211-28
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardized approach to the treatment of adult soft tissue sarcoma of the extremities.
  • Soft tissue sarcomas are very rare tumors.
  • Furthermore, universally accepted treatment protocols for adult patients are lacking.
  • Several prognostic factors have been identified, including grading, tumor size and development of metastatic disease; however, the relevance of other important aspects in the treatment of patients with soft tissue sarcomas remains unknown or subject to controversy.
  • [MeSH-major] Extremities / pathology. Extremities / surgery. Sarcoma / therapy
  • [MeSH-minor] Adult. Humans

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230542.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 84
  •  go-up   go-down


17. Badellino F, Toma S: Treatment of soft tissue sarcoma: a European approach. Surg Oncol Clin N Am; 2008 Jul;17(3):649-72, x
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of soft tissue sarcoma: a European approach.
  • This article discusses the treatment of adult soft tissue sarcoma (excluding gastrointestinal stromal tumor), analyzing the principles underlying treatment and the results of surgery, radiotherapy, and chemotherapy.
  • [MeSH-major] Sarcoma / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486888.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 82
  •  go-up   go-down


18. Lubieniecka JM, Nielsen TO: cDNA microarray-based translational research in soft tissue sarcoma. J Surg Oncol; 2005 Dec 15;92(4):267-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] cDNA microarray-based translational research in soft tissue sarcoma.
  • The authors discuss application of cDNA microarray technology in translational research to identify diagnostic markers and therapeutic targets in adult soft tissue sarcoma.
  • Recent results in synovial sarcoma are used to highlight the applicability of this technology for marker and target discovery, as well as the need for preclinical validation of putative therapeutic targets.
  • [MeSH-major] Gene Expression Profiling. Oligonucleotide Array Sequence Analysis. Sarcoma / genetics. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adult. Gastrointestinal Stromal Tumors / genetics. Humans. Molecular Diagnostic Techniques. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / genetics

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16299802.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Editorial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Hartmann JT, Patel S: New drug developments for patients with metastatic soft tissue sarcoma. Curr Oncol Rep; 2005 Jul;7(4):300-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New drug developments for patients with metastatic soft tissue sarcoma.
  • However, the number of effective cytotoxic agents for the treatment of patients with metastatic so-called adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Curr Oncol Rep. 2012 Apr;14(2):220 [22371000.001]
  • [Cites] Anticancer Drugs. 2002 May;13 Suppl 1:S7-9 [12173492.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1329-34 [11870176.001]
  • [Cites] Cancer Treat Rep. 1976 Feb;60(2):199-203 [769974.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):561-4 [12477998.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):48-51 [12694653.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1318-29 [12763223.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1248-55 [11230465.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2848-52 [12767099.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2579-82 [11289134.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Invest New Drugs. 2002 Feb;20(1):129-32 [12003189.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Jul;9(7):1545-51 [11060759.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1281-8 [11697841.001]
  • [Cites] Anticancer Drugs. 2000 Jun;11(5):325-9 [10912948.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1899-901 [12820475.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(3):263-5 [7781149.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):410-2 [10448291.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1969-73 [12673725.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2181-8 [11956280.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Anticancer Drugs. 1999 Jun;10(5):453-6 [10477164.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Ann Oncol. 1995 Oct;6(8):847-9 [8589028.001]
  • [Cites] Clin Ter. 1999 Jan-Feb;150(1):17-20 [10367540.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1664-71 [15378498.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2937-47 [11387367.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2248-52 [8635028.001]
  • [Cites] Anticancer Drugs. 1999 Nov;10(10):873-7 [10630354.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3225-9 [12115355.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):383-93 [11839653.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Cancer. 2003 Dec 15;98 (12 ):2693-9 [14669291.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3263-8 [12115359.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S174-9 [8453693.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1526-31 [8622067.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3463-9 [11481351.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] J Med Chem. 1984 Feb;27(2):196-201 [6694168.001]
  • [Cites] J Med Chem. 1986 Aug;29(8):1553-5 [3735324.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):422-3 [9640234.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • (PMID = 15946590.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  •  go-up   go-down


20. Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, Jimeno J, D'Incalci M, Gescher A, Casali PG: Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer; 2006 Jul;42(10):1484-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
  • Trabectedin is a marine-derived cytoxic alkaloid which has shown promising antitumour activity in a variety of human malignancies including sarcoma.
  • Fifty-four patients with advanced sarcoma (age 43 yrs, range 18-70), all pretreated with prior chemotherapy, were enrolled on a named individual basis for treatment with trabectedin.
  • Diagnosis was adult soft tissue sarcoma (STS) in 46 patients, Ewing's family tumour (EFT) in 4, and osteosarcoma (OS) in 4.
  • Among STS patients, 9% had objective responses.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Bone Marrow Diseases / chemically induced. Dioxoles / adverse effects. Drug-Induced Liver Injury. Premedication. Sarcoma / drug therapy. Steroids / therapeutic use. Tetrahydroisoquinolines / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Liver Diseases / prevention & control. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737808.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Steroids; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  •  go-up   go-down


21. de Bree R, van der Waal I, de Bree E, Leemans CR: Management of adult soft tissue sarcomas of the head and neck. Oral Oncol; 2010 Nov;46(11):786-90
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adult soft tissue sarcomas of the head and neck.
  • Adult soft tissue sarcoma of the head and neck are rare and represent a heterogeneous group of tumours of different histological variants.
  • Malignant fibrous histiocytoma, fibrosarcoma, angiosarcoma and malignant peripheral nerve sheath tumour are the most frequently found sarcoma types in the head and neck.
  • The management of soft tissue sarcomas in the head and neck is primarily surgical.
  • With further insight into the biology of soft tissue sarcoma, modern imaging techniques and new treatment options, we will most certainly be able to improve clinical outcome in patients with soft tissue sarcoma in the upcoming years.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20947413.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


22. Abdel-Hamed MF, Hussein HA, Helmy NA, Elsaie ML: The detection of steroid sulfatase gene deletion (STS) in Egyptian males with X-linked ichthyosis. J Drugs Dermatol; 2010 Oct;9(10):1192-6
Genetic Alliance. consumer health - X-linked ichthyosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of steroid sulfatase gene deletion (STS) in Egyptian males with X-linked ichthyosis.
  • The identification of steroid sulfatase (STS) as the cause of X-linked ichthyosis (XLI) points to the importance of this enzyme in skin desquamation.
  • Fluorescent in situ hybridization (FISH) analysis is a good diagnostic technique with which to detect a common deletion of the STS gene.
  • OBJECTIVE: In this study, the authors set out to detect the X-linked type of ichthyosis, diagnosed by detection of STS gene deletions among Egyptian males.
  • METHODOLOGY: Egyptian males complaining of X-linked ichthyosis were clinically examined, evaluating pedigree analysis of the family, cytogenetic studies using G-banding technique and FISH using locus specific probe for steroid sulfatase (STS) gene which is located at chromosome Xp22.3.
  • RESULTS: Of patients, 11.11 percent had nocturnal enuresis and 33.33 percent showed STS gene deletion by FISH analysis.
  • FISH analysis is a good, reliable and rapid diagnostic tool with which to detect STS gene deletion.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. In Situ Hybridization, Fluorescence. Infant. Male

  • Genetic Alliance. consumer health - Ichthyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941942.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.6.2 / Steryl-Sulfatase
  •  go-up   go-down


23. Jacobs ML, Mavroudis C, Jacobs JP, Tchervenkov CI, Pelletier GJ: Report of the 2005 STS Congenital Heart Surgery Practice and Manpower Survey. Ann Thorac Surg; 2006 Sep;82(3):1152-8, 1159e1-5; discussion 1158-9
MedlinePlus Health Information. consumer health - Congenital Heart Defects.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of the 2005 STS Congenital Heart Surgery Practice and Manpower Survey.
  • To obtain reliable data, The Society of Thoracic Surgeons (STS) Workforce on Congenital Heart Surgery undertook a subspecialty focused survey.
  • Surveys were sent to these, plus any additional individuals who listed an interest in congenital or pediatric heart surgery on CTSNet or STS websites.
  • Responders include active congenital heart surgeons, inactive, or retired surgeons, adult cardiac surgeons, and surgeons in training.
  • [MeSH-minor] Adult. Aged. Attitude of Health Personnel. Canada. Data Collection. Education, Medical, Graduate / statistics & numerical data. Faculty, Medical / statistics & numerical data. Female. Foreign Medical Graduates / statistics & numerical data. Humans. Job Satisfaction. Male. Middle Aged. Physicians / psychology. Professional Practice / statistics & numerical data. Schools, Medical / statistics & numerical data. Societies, Medical. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928571.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Gronchi A, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L, Casali PG: Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. Ann Surg Oncol; 2007 May;14(5):1583-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure.
  • BACKGROUND: We explored the prognostic meaning of local relapse and surgical margins in adult soft tissue sarcoma of the extremities.
  • METHODS: Out of a series of 1017 patients with extremity soft tissue sarcoma treated over 20 years, we picked a group of 238 patients operated on at our institution for their first local relapse: 88 after their primary operation performed at the same center and 150 elsewhere.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lower Extremity / pathology. Male. Middle Aged. Neoplasm Metastasis / pathology. Prognosis. Survival Rate. Treatment Failure. Upper Extremity / pathology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2007 May;14(5):1528-9 [17295083.001]
  • (PMID = 17260106.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Pfragner R, Behmel A, Höger H, Beham A, Ingolic E, Stelzer I, Svejda B, Moser VA, Obenauf AC, Siegl V, Haas O, Niederle B: Establishment and characterization of three novel cell lines - P-STS, L-STS, H-STS - derived from a human metastatic midgut carcinoid. Anticancer Res; 2009 Jun;29(6):1951-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of three novel cell lines - P-STS, L-STS, H-STS - derived from a human metastatic midgut carcinoid.
  • The reason for the poor success in establishing carcinoid cell lines is due to the small amount of tissue available and the low mitotic activity in primary cultures.
  • We have successfully established three continuously growing cell lines from tissue obtained from a metastatic human carcinoid of the terminal ileum (midgut carcinoid): P-STS was derived from the primary tumor, L-STS from a lymph node metastasis and H-STS from a hepatic metastasis.
  • Mutation screening of P-STS excluded a MEN1-gene-associated genetic predisposition with high probability.
  • The novel cell lines P-STS, L-STS and H-STS may be useful in vitro and in vivo models for further studies of biological characteristics and the development of new therapeutic agents.
  • [MeSH-minor] Adult. Animals. Chromosomes, Human, Pair 18 / genetics. Comparative Genomic Hybridization. Cryopreservation. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Mice. Mice, SCID. Mutation / genetics. Oligonucleotide Array Sequence Analysis. Ploidies. Proto-Oncogene Proteins / genetics. Tumor Cells, Cultured. Xenograft Model Antitumor Assays


26. Bonmatí A, Arsuaga JL, Lorenzo C: Revisiting the developmental stage and age-at-death of the "Mrs. Ples" (Sts 5) and Sts 14 specimens from Sterkfontein (South Africa): do they belong to the same individual? Anat Rec (Hoboken); 2008 Dec;291(12):1707-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting the developmental stage and age-at-death of the "Mrs. Ples" (Sts 5) and Sts 14 specimens from Sterkfontein (South Africa): do they belong to the same individual?
  • During the 1947 fieldwork season, Member 4 (2-3 My) of the South African Sterkfontein site yielded two important Australopithecus africanus fossils: a cranium popularly nicknamed "Mrs. Ples" (Sts 5), and a partial skeleton (Sts 14).
  • Previous reports have proposed that Sts 5 was a nonfully grown adolescent individual (Thackeray et al., S Afr J Sci 2002a;98:21-22), and that Sts 14 was a sub-adult specimen (according to various signs of immaturity in the skeleton) (Berge and Gommery, C R Acad Sci Paris, Sciences de la terre et des planètes 1999;329:227-232; Häusler and Berger, J Hum Evol, 2001;40:411-417; Thackeray et al., S Afr J Sci, 2002b;98:211-212).
  • The results obtained: (i) show that the Sts 5 fossil represents a fully grown adult cranium;.
  • (ii) provide new evidence of immaturity in the Sts 14 skeletal elements (sustaining the proposed young adult age of this specimen), and (iii) suggest that although the revised ages-at-death for these fossils are partially compatible, there is no evidence to support the idea that they represent a single individual.
  • Finally, the encephalization quotient associated with a hypothetical union of Sts 5 and Sts 14 (calculated using data from both specimens) lies between the upper and lower limits of the currently estimated range for this species and H. habilis, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18951512.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Iellamo F, Di Rienzo M, Lucini D, Legramante JM, Pizzinelli P, Castiglioni P, Pigozzi F, Pagani M, Parati G: Muscle metaboreflex contribution to cardiovascular regulation during dynamic exercise in microgravity: insights from mission STS-107 of the space shuttle Columbia. J Physiol; 2006 May 1;572(Pt 3):829-38
MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscle metaboreflex contribution to cardiovascular regulation during dynamic exercise in microgravity: insights from mission STS-107 of the space shuttle Columbia.
  • Four astronauts participating in the 16 day Columbia shuttle mission (STS-107) were studied 72-71 days before launch and on days 12-13 in-flight.
  • [MeSH-minor] Adaptation, Physiological / physiology. Adult. Blood Pressure / physiology. Exercise Test. Female. Humans. Male. Middle Aged. Physical Fitness / physiology. Sample Size. United States. United States National Aeronautics and Space Administration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hypertens. 2000 Jan;18(1):7-19 [10678538.001]
  • [Cites] Neurosci Lett. 2000 Feb 11;280(1):49-52 [10696809.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2000 Mar;278(3):H818-28 [10710350.001]
  • [Cites] Circulation. 2001 Apr 10;103(14):1851-7 [11294802.001]
  • [Cites] J Appl Physiol (1985). 2001 May;90(5):1714-9 [11299260.001]
  • [Cites] Ital Heart J. 2001 Mar;2(3):200-12 [11305532.001]
  • [Cites] J Appl Physiol (1985). 2001 Aug;91(2):645-53 [11457776.001]
  • [Cites] Auton Neurosci. 2001 Jul 20;90(1-2):66-75 [11485294.001]
  • [Cites] Eur J Appl Physiol. 2001 Jul;85(1-2):49-55 [11513320.001]
  • [Cites] Auton Neurosci. 2001 Aug 13;91(1-2):85-95 [11515805.001]
  • [Cites] Hypertension. 2002 Jan;39(1):184-8 [11799100.001]
  • [Cites] Circulation. 2002 Jun 11;105(23):2719-24 [12057984.001]
  • [Cites] J Physiol. 2002 Aug 15;543(Pt 1):349-64 [12181305.001]
  • [Cites] J Physiol. 2002 Oct 15;544(Pt 2):653-64 [12381834.001]
  • [Cites] J Physiol. 1980 Dec;309:45-54 [7252875.001]
  • [Cites] Circ Res. 1982 Jan;50(1):125-32 [6119167.001]
  • [Cites] Hypertension. 1982 Mar-Apr;4(2):245-50 [7068183.001]
  • [Cites] J Appl Physiol Respir Environ Exerc Physiol. 1983 Jul;55(1 Pt 1):105-12 [6309712.001]
  • [Cites] Circ Res. 1985 Sep;57(3):461-9 [4028348.001]
  • [Cites] J Clin Invest. 1987 Feb;79(2):508-16 [3805279.001]
  • [Cites] Am J Physiol. 1987 Oct;253(4 Pt 2):H787-91 [2889371.001]
  • [Cites] J Physiol. 1987 Aug;389:557-68 [3681737.001]
  • [Cites] Am J Physiol. 1987 Nov;253(5 Pt 2):H1199-207 [3688260.001]
  • [Cites] Am J Physiol. 1988 Feb;254(2 Pt 2):H377-83 [3344828.001]
  • [Cites] J Appl Physiol (1985). 1988 Jun;64(6):2306-13 [3136123.001]
  • [Cites] Hypertension. 1988 Aug;12(2):214-22 [3410530.001]
  • [Cites] Hypertension. 1988 Dec;12(6):600-10 [3203964.001]
  • [Cites] Am J Physiol. 1989 Dec;257(6 Pt 2):H2017-24 [2603985.001]
  • [Cites] Circulation. 1990 Feb;81(2):518-27 [2297859.001]
  • [Cites] Med Sci Sports Exerc. 1990 Apr;22(2):141-54 [2192221.001]
  • [Cites] J Appl Physiol (1985). 1990 Aug;69(2):407-18 [2228848.001]
  • [Cites] Hypertension. 1991 Aug;18(2):230-5 [1909305.001]
  • [Cites] Circulation. 1991 Nov;84(5):2034-9 [1934378.001]
  • [Cites] Circulation. 1992 May;85(5):1751-9 [1315220.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2000 Feb;278(2):H530-7 [10666085.001]
  • [Cites] J Appl Physiol (1985). 1992 Aug;73(2):664-71 [1399995.001]
  • [Cites] J Appl Physiol (1985). 1993 Apr;74(4):1748-54 [8514692.001]
  • [Cites] J Appl Physiol (1985). 1993 Sep;75(3):1426-31 [8226561.001]
  • [Cites] Clin Investig. 1993 Sep;71(9):704-9 [8241720.001]
  • [Cites] Am J Physiol. 1993 Dec;265(6 Pt 2):H1928-38 [8285231.001]
  • [Cites] J Appl Physiol (1985). 1994 Aug;77(2):502-6 [8002493.001]
  • [Cites] Circulation. 1996 Mar 1;93(5):940-52 [8598085.001]
  • [Cites] Med Sci Sports Exerc. 1996 Feb;28(2):210-7 [8775156.001]
  • [Cites] J Appl Physiol (1985). 1996 Jul;81(1):26-32 [8828644.001]
  • [Cites] J Appl Physiol (1985). 1996 Jul;81(1):105-16 [8828652.001]
  • [Cites] J Appl Physiol (1985). 1996 Aug;81(2):686-94 [8872635.001]
  • [Cites] J Hypertens. 1995 Dec;13(12 Pt 2):1660-3 [8903628.001]
  • [Cites] Eur J Appl Physiol Occup Physiol. 1997;75(2):89-96 [9118988.001]
  • [Cites] J Physiol. 1997 Jun 15;501 ( Pt 3):677-86 [9218227.001]
  • [Cites] Int J Sports Med. 1997 Oct;18 Suppl 4:S308-9 [9391844.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 2):H220-4 [9688917.001]
  • [Cites] J Appl Physiol (1985). 1999 Jan;86(1):174-80 [9887128.001]
  • [Cites] Int J Cardiol. 1999 Feb 28;68(2):157-64 [10189003.001]
  • [Cites] Am J Physiol. 1999 Apr;276(4 Pt 2):H1399-403 [10199868.001]
  • [Cites] Circulation. 1999 Jul 6;100(1):27-32 [10393677.001]
  • [Cites] J Appl Physiol (1985). 1999 Jul;87(1):332-8 [10409592.001]
  • [Cites] J Appl Physiol (1985). 2005 Jul;99(1):5-22 [16036901.001]
  • [Cites] J Physiol. 2005 Jul 15;566(Pt 2):599-611 [15890708.001]
  • [Cites] Int J Cardiol. 1988 Feb;18(2):187-95 [2830194.001]
  • [CommentIn] J Physiol. 2006 May 1;572(Pt 3):607-8 [16543263.001]
  • (PMID = 16469787.001).
  • [ISSN] 0022-3751
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1779995
  •  go-up   go-down


28. Evans SR, Yeh TM, Sacktor N, Clifford DB, Simpson D, Miller EN, Ellis RJ, Valcour V, Marra CM, Millar L, Schifitto G, AIDS Clinical Trials Group and the Neurologic AIDS Research Consortium: Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials; 2007 Nov-Dec;8(6):437-46
Hazardous Substances Data Bank. SELEGILINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090.
  • OBJECTIVE: To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline Transdermal System (STS) for the treatment of HIV-associated cognitive impairment.
  • We conducted and reported a 24-week, double-blind, placebo-controlled study with STS in HIV-infected individuals with cognitive impairment (ACTG 5090).
  • METHOD: Subjects received either 3 mg/24 h or 6 mg/24 h STS daily.
  • [MeSH-minor] Administration, Cutaneous. Adult. Female. Humans. Male. Middle Aged. Neuropsychological Tests / statistics & numerical data

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18042509.001).
  • [ISSN] 1528-4336
  • [Journal-full-title] HIV clinical trials
  • [ISO-abbreviation] HIV Clin Trials
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 2 U01 NS0322228-08A1; United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAAA NIH HHS / AA / AA69495; United States / NIAID NIH HHS / AI / AI038855; United States / NIAID NIH HHS / AI / AI06863; United States / NIAID NIH HHS / AI / AI068634; United States / NIAID NIH HHS / AI / AI25903; United States / NIAID NIH HHS / AI / AI25915; United States / NIAID NIH HHS / AI / AI27658; United States / NIAID NIH HHS / AI / AI27659; United States / NIAID NIH HHS / AI / AI27660; United States / NIAID NIH HHS / AI / AI27664; United States / NIAID NIH HHS / AI / AI27668; United States / NIAID NIH HHS / AI / AI27670; United States / NIAID NIH HHS / AI / AI34853; United States / NIAID NIH HHS / AI / AI38858; United States / NIAID NIH HHS / AI / AI46370; United States / NIAID NIH HHS / AI / AI46376; United States / NIAID NIH HHS / AI / AI46381; United States / NIAID NIH HHS / AI / AI46386; United States / NIAID NIH HHS / AI / AI69423; United States / NIAID NIH HHS / AI / AI69424; United States / NIAID NIH HHS / AI / AI69432; United States / NIAID NIH HHS / AI / AI69434; United States / NIAID NIH HHS / AI / AI69465; United States / NIAID NIH HHS / AI / AI69467; United States / NIAID NIH HHS / AI / AI69470; United States / NIAID NIH HHS / AI / AI69471; United States / NIAID NIH HHS / AI / AI69472; United States / NIAID NIH HHS / AI / AI69494; United States / NIAID NIH HHS / AI / AI69495; United States / NIAID NIH HHS / AI / AI69511; United States / NIMH NIH HHS / MH / MH64409; United States / NCRR NIH HHS / RR / RR00044; United States / NIAID NIH HHS / AI / U01-AI-35040; United States / NIAID NIH HHS / AI / U01-AI-35041; United States / NIAID NIH HHS / AI / U01-AI-35042; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NIAID NIH HHS / AI / U01-AI-37613; United States / NIAID NIH HHS / AI / U01-AI-37984
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 2K1V7GP655 / Selegiline
  •  go-up   go-down


29. Liu A, Xiao S, Tan S, Lei X, Zhang J, Jiao T, Liu Y: STS gene in a pedigree with X-linked ichthyosis. J Huazhong Univ Sci Technolog Med Sci; 2005;25(4):468-9
Genetic Alliance. consumer health - X-linked ichthyosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STS gene in a pedigree with X-linked ichthyosis.
  • To investigate the gene mutation in a pedigree with X-linked ichthyosis (XLI) and to explore the relationship between the mutation and its clinical manifestations, genomic DNA of affected members, the normal member of the pedigree and 50 unrelated normal members was extracted with a whole blood genomic DNA extraction kit and the DNA was used as a template for the polymerase chain reaction (PCR)-mediated amplification of exon 1 and exon 10 of the STS gene. hHb6 (human hair basic keratin) gene was used as the internal control.
  • Our results showed that the STS gene was deleted in affected members in the pedigree with X-linked ichthyosis.
  • It is concluded that deletion of the STS gene existed in this pedigree with X-linked ichthyosis, and it is responsible for the unique skin lesions of X-linked ichthyosis.
  • [MeSH-minor] Adult. Female. Humans. Male. Pedigree

  • Genetic Alliance. consumer health - Ichthyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):456-8 [11231321.001]
  • [Cites] Hum Genet. 1990 May;84(6):571-3 [2338343.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):617-27 [10583107.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Nov;86(21):8477-81 [2813406.001]
  • [Cites] Dermatology. 2003;207(2):148-50 [12920363.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Aug;59(2):263-4 [12864806.001]
  • [Cites] Nature. 1961 Apr 22;190:372-3 [13764598.001]
  • (PMID = 16196306.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.1.6.2 / Steryl-Sulfatase
  •  go-up   go-down


30. Sator-Katzenschlager S, Fiala K, Kress HG, Kofler A, Neuhold J, Kloimstein H, Ilias W, Mozes-Balla EM, Pinter M, Loining N, Fuchs W, Heinze G, Likar R: Subcutaneous target stimulation (STS) in chronic noncancer pain: a nationwide retrospective study. Pain Pract; 2010 Jul-Aug;10(4):279-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous target stimulation (STS) in chronic noncancer pain: a nationwide retrospective study.
  • We describe the results with a new neurostimulation technique, subcutaneous target stimulation (STS), for the treatment of chronic focal noncancer pain.
  • STS applies permanent electrical stimulation directly at the painful area via a percutaneous-placed subcutaneous lead.
  • We reported the clinical outcomes of 111 patients with focal chronic, noncancer pain treated with STS in this first nationwide, multicenter retrospective analysis.
  • The indications for STS were low back pain (n = 29) and failed back surgery syndrome (back pain with leg pain) (n = 37), cervical neck pain (n = 15), and postherpetic neuralgia (n = 12).
  • In all the patients, the STS leads were positioned directly at the site of maximum pain.
  • The retrospective data analysis revealed that STS effectively provided pain relief in patients suffering from refractory focal chronic noncancer pain and that STS is an alternative treatment option.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analgesics / therapeutic use. Austria. Biophysics. Chronic Disease. Electrodes, Implanted. Female. Humans. Male. Middle Aged. Pain / classification. Pain / drug therapy. Pain Measurement / methods. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230450.001).
  • [ISSN] 1533-2500
  • [Journal-full-title] Pain practice : the official journal of World Institute of Pain
  • [ISO-abbreviation] Pain Pract
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics
  •  go-up   go-down


31. Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E: A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs; 2006 Sep;24(5):435-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
  • BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins.
  • CONCLUSIONS: Perifosine when given according to this dosing schedule does not show evidence of activity in a mixed population of adult soft tissue sarcoma patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Phosphorylcholine / analogs & derivatives. Sarcoma / drug therapy
  • [MeSH-minor] Academies and Institutes. Adult. Aged. Canada. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasms / drug therapy


32. Elkashef A, Fudala PJ, Gorgon L, Li SH, Kahn R, Chiang N, Vocci F, Collins J, Jones K, Boardman K, Sather M: Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend; 2006 Dec 1;85(3):191-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.
  • In this study, selegiline transdermal system (STS) was compared to placebo as a treatment for cocaine dependence.
  • [MeSH-minor] Administration, Cutaneous. Adult. Double-Blind Method. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Cocaine.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SELEGILINE HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730924.001).
  • [ISSN] 0376-8716
  • [Journal-full-title] Drug and alcohol dependence
  • [ISO-abbreviation] Drug Alcohol Depend
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / Y1-DA1001
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Monoamine Oxidase Inhibitors; 2K1V7GP655 / Selegiline
  •  go-up   go-down


33. Yaseen Z, Katz C, Johnson MS, Eisenberg D, Cohen LJ, Galynker II: Construct development: The Suicide Trigger Scale (STS-2), a measure of a hypothesized suicide trigger state. BMC Psychiatry; 2010;10:110
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Construct development: The Suicide Trigger Scale (STS-2), a measure of a hypothesized suicide trigger state.
  • BACKGROUND: This study aims to develop the construct of a 'suicide trigger state' by exploring data gathered with a novel psychometric self-report instrument, the STS-2.
  • METHODS: The STS-2, was administered to 141 adult psychiatric patients with suicidal ideation.
  • CONCLUSIONS: The STS-2 appears to measure a distinct and novel clinical entity, which we speculatively term the 'suicide trigger state.
  • ' High scores on the STS-2 associate with reported history of past suicide attempt.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Factor Analysis, Statistical. Female. Humans. Male. Middle Aged. Models, Psychological. Psychometrics. Reproducibility of Results. Self Report. Suicide, Attempted / psychology. Suicide, Attempted / statistics & numerical data. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • MedlinePlus Health Information. consumer health - Suicide.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Suicide Life Threat Behav. 2003 Winter;33(4):389-99 [14695054.001]
  • [Cites] Psychiatr Clin North Am. 2003 Jun;26(2):457-94, x [12778843.001]
  • [Cites] J Consult Clin Psychol. 1979 Apr;47(2):343-52 [469082.001]
  • [Cites] Am J Psychiatry. 1985 May;142(5):559-63 [3985195.001]
  • [Cites] N Engl J Med. 1989 Nov 2;321(18):1209-14 [2797086.001]
  • [Cites] Crisis. 1990 May;11(1):52-9 [2376147.001]
  • [Cites] Crisis. 1990 Nov;11(2):22-30 [2076612.001]
  • [Cites] Epidemiology. 1990 Jan;1(1):43-6 [2081237.001]
  • [Cites] Am J Psychiatry. 1993 Jun;150(6):928-34 [8494071.001]
  • [Cites] J Affect Disord. 1994 Dec;32(4):253-6 [7897089.001]
  • [Cites] Am J Psychiatry. 1996 May;153(5):667-73 [8615412.001]
  • [Cites] J Clin Psychiatry. 1996 Sep;57(9):402-6 [9746448.001]
  • [Cites] Am J Psychiatry. 1999 Feb;156(2):181-9 [9989552.001]
  • [Cites] Psychosomatics. 1999 Jan-Feb;40(1):18-27 [9989117.001]
  • [Cites] Gen Hosp Psychiatry. 1999 Jan-Feb;21(1):62-9 [10068922.001]
  • [Cites] Am J Psychiatry. 1999 Oct;156(10):1590-5 [10518171.001]
  • [Cites] J Nerv Ment Dis. 2004 Dec;192(12):837-42 [15583505.001]
  • [Cites] Suicide Life Threat Behav. 2004 Winter;34(4):386-94 [15585460.001]
  • [Cites] Br J Gen Pract. 2005 Apr;55(513):269-73 [15826433.001]
  • [Cites] J Affect Disord. 2005 Jun;86(2-3):225-33 [15935242.001]
  • [Cites] J Clin Psychiatry. 2005 Jun;66(6):693-704 [15960561.001]
  • [Cites] JAMA. 2005 Aug 3;294(5):563-70 [16077050.001]
  • [Cites] Nord J Psychiatry. 2006;60(2):162-7 [16635937.001]
  • [Cites] Acta Psychiatr Scand. 2006 Sep;114(3):151-8 [16889585.001]
  • [Cites] Eur Psychiatry. 2006 Oct;21(7):471-7 [16545548.001]
  • [Cites] Psychosom Med. 2007 Dec;69(9):841-5 [18040091.001]
  • [Cites] Dan Med Bull. 2007 Nov;54(4):306-69 [18208680.001]
  • [Cites] Br J Psychol. 2008 May;99(Pt 2):191-209 [17559717.001]
  • [Cites] Suicide Life Threat Behav. 2008 Oct;38(5):523-38 [19014305.001]
  • [Cites] J Nerv Ment Dis. 2009 Feb;197(2):92-7 [19214043.001]
  • [Cites] J Clin Psychiatry. 2009 Jan;70(1):19-24 [19026258.001]
  • [Cites] J Psychiatr Res. 2009 Jun;43(9):825-9 [19147159.001]
  • [Cites] Psychiatry Res. 1999 Nov 8;88(2):153-61 [10622351.001]
  • [Cites] J Consult Clin Psychol. 2000 Jun;68(3):371-7 [10883553.001]
  • [Cites] Eur Psychiatry. 2000 Nov;15(7):416-23 [11112934.001]
  • [Cites] Med J Aust. 2001 Mar 5;174(5):222-6 [11280692.001]
  • [Cites] J Clin Child Adolesc Psychol. 2002 Mar;31(1):48-58 [11845650.001]
  • [Cites] Psychopathology. 2001 Nov-Dec;34(6):278-88 [11847487.001]
  • [Cites] J Clin Psychiatry. 2003 Jan;64(1):14-9 [12590618.001]
  • [Cites] Control Clin Trials. 2004 Feb;25(1):119-42 [15061154.001]
  • (PMID = 21144063.001).
  • [ISSN] 1471-244X
  • [Journal-full-title] BMC psychiatry
  • [ISO-abbreviation] BMC Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3016314
  •  go-up   go-down


34. Hartmann JT, Patel S: Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs; 2005;65(2):167-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
  • The number of effective cytotoxic agents for the treatment of patients with metastatic adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy.
  • Small round cell tumours (SRCTs), such as Ewing's sarcoma/primitive neuroectodermal tumour, desmoplastic SRCT and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies, which are treated with multimodality, dose-intensive, neoadjuvant protocols regardless of size or overt metastatic disease.
  • Most other high-grade (grading >I), so-called 'adult type', soft tissue sarcomas such as fibrosarcoma, liposarcoma, pleomorphic and synovial sarcomas are treated with an anthracycline-based regimen with or without ifosfamide as front-line therapy.
  • In relapsed 'adult type' soft tissue sarcomas, trofosfamide, gemcitabine and trabectedin (ecteinascidin 743) appear to be drugs associated with some activity and an acceptable toxicity profile.
  • A high activity has been reported for the taxanes, in particular for paclitaxel, in vascular sarcomas located in the scalp or face and in Kaposi's sarcoma.
  • It is interesting to note that the different drugs have particular effects in distinct subtypes of soft tissue sarcoma; however, it should be taken into account that the number of patients included in the phase II trials is limited.
  • Targeted therapy inhibiting vascular endothelial growth factor receptor, epidermal growth factor receptor, RAF kinase, c-KIT or platelet-derived growth factor receptors will continue to be tested in GIST patients refractory to imatinib and in other sarcoma histologies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Metastasis / drug therapy. Salvage Therapy. Sarcoma / drug therapy. Sarcoma / pathology


35. Salas S, Stoeckle E, Collin F, Bui B, Terrier P, Guillou L, Trassard M, Ranchere-Vince D, Gregoire F, Coindre JM: Superficial soft tissue sarcomas (S-STS): a study of 367 patients from the French Sarcoma Group (FSG) database. Eur J Cancer; 2009 Aug;45(12):2091-102
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial soft tissue sarcomas (S-STS): a study of 367 patients from the French Sarcoma Group (FSG) database.
  • AIM: The specific natural history of superficial soft tissue sarcomas (S-STS) has been rarely considered.
  • We describe the clinical characteristics of a large series of S-STS (N=367) from the French Sarcoma Group (GSF-GETO) database and analyse the prognostic factors affecting outcome.
  • The most frequent tumour types were unclassified sarcoma (24.3%) and leiomyosarcoma (22.3%).
  • STS with early invasion into but not through the underlying fascia had a significantly poorer MFS than with strict S-STS.
  • CONCLUSION: S-STS represent a separate category characterised by a better outcome.
  • Adequate surgery, i.e. wide resection, is essential in the management of S-STS.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Female. France / epidemiology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19351580.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


36. Salas S, Bui B, Stoeckle E, Terrier P, Ranchere-Vince D, Collin F, Leroux A, Guillou L, Michels JJ, Trassard M, Valo I, Robin YM, Marques B, Brouste V, Coindre JM: Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database. Ann Oncol; 2009 Jun;20(6):1127-35
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database.
  • BACKGROUND: Soft tissue sarcomas of the trunk wall (STS-TW) are usually studied together with soft tissue sarcomas of other locations.
  • We report a study on STS-TW forming part of the French Sarcoma Group database.
  • The most frequent tumor types were unclassified sarcoma (27.7%) and myogenic sarcoma (19.2%).
  • However, a separate analysis of STS-TW revealed a significant poor prognosis subgroup of patients with PHR.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179555.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Brookes KJ, Hawi Z, Park J, Scott S, Gill M, Kent L: Polymorphisms of the steroid sulfatase (STS) gene are associated with attention deficit hyperactivity disorder and influence brain tissue mRNA expression. Am J Med Genet B Neuropsychiatr Genet; 2010 Dec 5;153B(8):1417-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of the steroid sulfatase (STS) gene are associated with attention deficit hyperactivity disorder and influence brain tissue mRNA expression.
  • Previous studies in animals and humans have implicated the X-chromosome STS gene in the etiology of attentional difficulties and attention deficit hyperactivity disorder (ADHD).
  • This family based association study has fine mapped a region of the STS gene across intron 1 and 2 previously associated with ADHD, in an extended sample of 450 ADHD probands and their parents.
  • The over transmitted risk allele of rs12861247 was also associated with reduced STS mRNA expression in normal human post-mortem frontal cortex brain tissue compared to the non-risk allele (P = 0.01).
  • These results are consistent with the hypothesis arising from previous literature demonstrating that boys with deletions of the STS gene, and hence no STS protein are at a significantly increased risk of developing ADHD.
  • Furthermore, this study has established the brain tissue transcript of STS, which except from adipose tissue, differs from that seen in all other tissues investigated.

  • Genetic Alliance. consumer health - Attention Deficit Disorder.
  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • [Cites] Microsc Res Tech. 2001 Mar 15;52(6):746-52 [11276127.001]
  • [Cites] Biol Psychiatry. 2009 Aug 15;66(4):360-7 [19251250.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):650-4 [12426569.001]
  • [Cites] Neuropsychobiology. 2003;48(3):111-5 [14586159.001]
  • [Cites] Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I50-70 [15322957.001]
  • [Cites] Development. 1992 Sep;116(1):193-200 [1483387.001]
  • [Cites] J Neurosci. 1994 Feb;14(2):472-85 [7905511.001]
  • [Cites] Psychol Med. 1995 Jul;25(4):739-53 [7480451.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8 [9204677.001]
  • [Cites] Curr Opin Neurobiol. 1998 Apr;8(2):263-71 [9635212.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16798-809 [9642238.001]
  • [Cites] J Clin Psychiatry. 1998;59 Suppl 7:24-30 [9680050.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):6020-6 [10026229.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] J Endocrinol. 2006 Jul;190(1):129-39 [16837617.001]
  • [Cites] Am J Psychiatry. 2007 Jun;164(6):942-8 [17541055.001]
  • [Cites] Biol Psychiatry. 2007 Jun 15;61(12):1351-60 [17161381.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Jun-Jul;105(1-5):76-84 [17596930.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Oct;107(1-2):22-9 [17601726.001]
  • [Cites] Hum Hered. 2008;66(2):87-98 [18382088.001]
  • [Cites] J Med Genet. 2008 Aug;45(8):519-24 [18413370.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1531-5 [18937300.001]
  • [Cites] J Steroid Biochem Mol Biol. 2009 May;115(1-2):68-74 [19429462.001]
  • [Cites] Int J Neuropsychopharmacol. 2001 Sep;4(3):259-64 [11602031.001]
  • (PMID = 20862695.001).
  • [ISSN] 1552-485X
  • [Journal-full-title] American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • [ISO-abbreviation] Am. J. Med. Genet. B Neuropsychiatr. Genet.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / RNA, Messenger; EC 3.1.6.2 / Steryl-Sulfatase
  • [Other-IDs] NLM/ PMC3132592
  •  go-up   go-down


38. Bernbeck B, Bahci S, Meisel R, Troeger A, Schönberger S, Laws HJ, Kramm C, Wessalowski R, Koscielniak E, Dilloo D, Göbel U: Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS). Klin Padiatr; 2007 Nov-Dec;219(6):318-22
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
  • In nine patients (pts) with soft tissue sarcoma refractory to conventional therapy (incomplete response or relapse) intensified chemotherapy was administered combining 0.75 mg/m (2) topotecan, 100 mg/m (2) etoposide, 100 mg/m (2) carboplatin and 200 mg/m (2) cyclophosphamide on day 1-5 (TECC).
  • These data provide evidence that in very high risk pts refractory to standard high risk therapy, a combination of TECC chemotherapy and stem cell support is feasible in pts with incomplete remission respectively relapsed STS pts and demonstrates promising antineoplastic activity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Feasibility Studies. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm, Residual / surgery. Remission Induction. Time Factors. Topotecan / administration & dosage. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050041.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


39. Suppiah R, Wood L, Elson P, Budd GT: Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs; 2006 Nov;24(6):509-14
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
  • BACKGROUND: Based on reports of the efficacy of docetaxel (T) in STS, we undertook a phase I/II trial to determine the response rate (RR), dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of addition of T to doxorubicin (A) and ifosfamide (I) in advanced STS.
  • METHODS: Patients with advanced, recurrent, or metastatic STS, without prior chemotherapy, were enrolled in a dose escalation trial.
  • HISTOLOGY: leiomyosarcoma 10, spindle cell sarcoma 3, synovial sarcoma 2, angiosarcoma 1, fibrous histiocytoma 1, epitheliod hemangio-endothelioma 1, and 3 not specified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Survival Analysis. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 1995 Oct;20(3):193-201 [8748009.001]
  • [Cites] Cancer. 1981 May 15;47(10):2422-9 [7272896.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Ter. 1998 Mar-Apr;149(2):121-5 [9780476.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2757-62 [7139566.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1087-94 [10572607.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1281-8 [11697841.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2397-406 [12460784.001]
  • [Cites] Cancer. 1984 May 1;53(9):1825-32 [6367947.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • (PMID = 16791410.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


40. Akudugu JM, Bell RS, Catton C, Davis AM, Griffin AM, O'Sullivan B, Waldron JN, Ferguson PC, Wunder JS, Hill RP: Wound healing morbidity in STS patients treated with preoperative radiotherapy in relation to in vitro skin fibroblast radiosensitivity, proliferative capacity and TGF-beta activity. Radiother Oncol; 2006 Jan;78(1):17-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wound healing morbidity in STS patients treated with preoperative radiotherapy in relation to in vitro skin fibroblast radiosensitivity, proliferative capacity and TGF-beta activity.
  • BACKGROUND AND PURPOSE: In a recent study, we demonstrated that the ability of dermal fibroblasts, obtained from soft tissue sarcoma (STS) patients, to undergo initial division in vitro following radiation exposure correlated with the development of wound healing morbidity in the patients following their treatment with preoperative radiotherapy.
  • Thus, in this study we examined the interrelationship between TGF-beta activity, radiosensitivity and proliferation of cultured fibroblasts and the wound healing response of STS patients after preoperative radiotherapy to provide a validation cohort for our previous study and to investigate mechanisms.
  • PATIENTS AND METHODS: Skin fibroblasts were established from skin biopsies of 46 STS patients.
  • CONCLUSIONS: These data are consistent with our previous study and combined the results suggest that in vitro fibroblast proliferation after irradiation may be a useful predictor of wound healing morbidity in STS patients treated with preoperative radiotherapy.
  • [MeSH-major] Cell Proliferation / radiation effects. Fibroblasts / radiation effects. Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy. Transforming Growth Factor beta / metabolism. Wound Healing / radiation effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Nucleus / radiation effects. Cells, Cultured. Female. Humans. Linear Models. Male. Middle Aged. Preoperative Care. Radiation Tolerance. Regression Analysis. Skin / cytology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16380182.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta
  •  go-up   go-down


41. Stahl R, Wang T, Lindner LH, Abdel-Rahman S, Santl M, Reiser MF, Issels RD: Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS). Int J Hyperthermia; 2009 Jun;25(4):289-98
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
  • PURPOSE: To compare the radiological criteria RECIST, WHO, and tumor volume for evaluation of tumor response in patients with soft tissue sarcomas (STS) showing either good or poor pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia, and to examine the dependence of the findings on the applied thermal dose.
  • RECIST, WHO and volumetric criteria for response evaluation in STS are in substantial agreement.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Hyperthermia, Induced / methods. Ifosfamide / therapeutic use. Male. Middle Aged. Neoadjuvant Therapy. Thermography. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670096.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide; AVI protocol
  •  go-up   go-down


42. Schlemmer M, Wendtner CM, Lindner L, Abdel-Rahman S, Hiddemann W, Issels RD: Thermochemotherapy in patients with extremity high-risk soft tissue sarcomas (HR-STS). Int J Hyperthermia; 2010;26(2):127-35
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thermochemotherapy in patients with extremity high-risk soft tissue sarcomas (HR-STS).
  • PURPOSE: We report data from phase II trials examining the efficacy of multimodality treatment with neoadjuvant chemotherapy, hyperthermia, surgery, radiation and postoperative thermochemotherapy in adult patients with high-risk sarcomas of the extremities.
  • PATIENTS AND METHODS: From 1991 to 2001 47 patients with high risk soft tissue sarcoma of the extremities were prospectively treated in two clinical trials with a treatment plan of four cycles of etoposide, ifosfamide and doxorubicin combined with regional hyperthermia followed by surgery, radiation and adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hyperthermia, Induced. Neoadjuvant Therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146567.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


43. McDuffie HH, Pahwa P, Karunanayake CP, Spinelli JJ, Dosman JA: Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects. BMC Cancer; 2009;9:70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects.
  • METHODS: We conducted population-based studies of Hodgkin lymphoma (HL), Multiple Myeloma (MM), non-Hodgkin's Lymphoma (NHL), and Soft Tissue Sarcoma (STS) among male incident case and control subjects in six Canadian provinces.
  • The information was collected on 1528 cases (HL (n = 316), MM (n = 342), NHL (n = 513), STS (n = 357)) and 1506 age +/- 2 years and province of residence matched control subjects.
  • HL [(OR(adj) (95% CI) 1.79 (1.33, 2.42)], MM (1.38(1.07, 1.78)), NHL (1.43 (1.15, 1.77)), and STS cases (1.30(1.00, 1.68)) had higher incidence of cancer if any first degree relative was affected with cancer compared to control families.
  • CONCLUSION: HL, MM, NHL, and STS cases had higher incidence of cancer if any first degree relative affected with cancer compared to control families.
  • [MeSH-major] Hodgkin Disease / genetics. Lymphoma, Non-Hodgkin / genetics. Multiple Myeloma / genetics. Sarcoma / genetics
  • [MeSH-minor] Adult. Aged. Canada / epidemiology. Case-Control Studies. Cluster Analysis. Family Health. Female. Humans. Incidence. Male. Middle Aged. Surveys and Questionnaires


44. D'Annibale M, Cosimelli M, Covello R, Stasi E: Liposarcoma of the colon presenting as an endoluminal mass. World J Surg Oncol; 2009;7:78
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Liposarcoma is one of the most common soft tissue sarcoma of adult life, usually occurring in the retroperitoneum and the extremities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Apr;36(4):378-80 [10841651.001]
  • [Cites] Gastroenterol Clin Biol. 2009 Oct-Nov;33(10-11):1016-8 [19272723.001]
  • [Cites] Acta Oncol. 2003;42(5-6):516-31 [14596510.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):281-5 [15306943.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1257-67 [15371941.001]
  • [Cites] Am Surg. 2004 Sep;70(9):775-8 [15481292.001]
  • [Cites] Am J Gastroenterol. 1972 Aug;58(2):172-6 [5056514.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] Dis Colon Rectum. 1984 Jul;27(7):485-8 [6745024.001]
  • [Cites] Cancer. 1985 May 15;55(10):2482-90 [3986744.001]
  • [Cites] Acta Chir Scand. 1986 May;152:389-91 [3739551.001]
  • [Cites] Mt Sinai J Med. 1989 Jan;56(1):62-4 [2784186.001]
  • [Cites] Am J Surg Pathol. 1992 Nov;16(11):1051-8 [1471725.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1213-23 [7977944.001]
  • [Cites] Ulster Med J. 1994 Apr;63(1):111-3 [8658985.001]
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):398-407 [9164509.001]
  • [Cites] Eur J Cancer. 2005 Dec;41(18):2853-60 [16289617.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] J Gastrointest Surg. 2006 May;10(5):652-6 [16773759.001]
  • [Cites] Dig Dis Sci. 2007 Dec;52(12):3377-80 [17393311.001]
  • [Cites] Surg Clin North Am. 2008 Jun;88(3):483-520, v-vi [18514695.001]
  • [Cites] Surg Today. 2008;38(12):1129-32 [19039641.001]
  • [Cites] J Gastrointest Cancer. 2007;38(2-4):160-3 [18972225.001]
  • [Cites] Am J Clin Oncol. 2009 Aug;32(4):353-5 [19363435.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):179-84 [11266523.001]
  • (PMID = 19852822.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2771004
  •  go-up   go-down


45. Bolling SF, Li S, O'Brien SM, Brennan JM, Prager RL, Gammie JS: Predictors of mitral valve repair: clinical and surgeon factors. Ann Thorac Surg; 2010 Dec;90(6):1904-11; discussion 1912
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Utilizing The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD), a multivariable model was created that included patient clinical characteristics and surgeon-specific mitral volume to predict the likelihood of mitral valve repair.
  • METHODS: Between January 2005 and December 2007, 28,507 patients undergoing isolated mitral valve surgery (with or without tricuspid valve surgery, with or without atrial fibrillation surgery) by 1,088 surgeons at 639 hospitals in the STS ACSD were identified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 21095334.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


46. Centini C, Pompeiano O: Sleep research in space: expression of immediate early genes in forebrain structures of rats during the nasa neurolab mission (STS-90). Arch Ital Biol; 2007 May;145(2):117-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sleep research in space: expression of immediate early genes in forebrain structures of rats during the nasa neurolab mission (STS-90).
  • 2. Both Fos and FRA expression were evaluated in several adult albino rats sacrificed at different time points of the space flight, i.e. either at FD2 and FD14, i.e. at launch and about two weeks after launch, respectively, or at R + 1 and R + 13, i.e. at the reentry and about two weeks after landing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639784.001).
  • [ISSN] 0003-9829
  • [Journal-full-title] Archives italiennes de biologie
  • [ISO-abbreviation] Arch Ital Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Proto-Oncogene Proteins c-fos; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


47. Oteo J, Cercenado E, Cuevas O, Bautista V, Delgado-Iribarren A, Orden B, Pérez-Vázquez M, García-Cobos S, Campos J: AmpC beta-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Diagn Microbiol Infect Dis; 2010 Jul;67(3):270-6
MedlinePlus Health Information. consumer health - E. Coli Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AmpC beta-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Female. Genotype. Humans. Male. Microbial Sensitivity Tests / methods. Middle Aged. Molecular Epidemiology. Prevalence. Spain / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20462723.001).
  • [ISSN] 1879-0070
  • [Journal-full-title] Diagnostic microbiology and infectious disease
  • [ISO-abbreviation] Diagn. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; EC 3.5.2.6 / AmpC beta-lactamases; EC 3.5.2.6 / beta-Lactamases
  •  go-up   go-down


48. Schwarzbach MH, Hormann Y, Hinz U, Bernd L, Willeke F, Mechtersheimer G, Böckler D, Schumacher H, Herfarth C, Büchler MW, Allenberg JR: Results of limb-sparing surgery with vascular replacement for soft tissue sarcoma in the lower extremity. J Vasc Surg; 2005 Jul;42(1):88-97
Hazardous Substances Data Bank. TEFLON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of limb-sparing surgery with vascular replacement for soft tissue sarcoma in the lower extremity.
  • OBJECTIVE: To evaluate limb-salvage surgery with vascular resection for lower extremity soft tissue sarcomas (STS) in adult patients and to classify blood vessel involvement.
  • METHODS: Subjects were consecutive patients (median age, 56 years) who underwent vascular replacement during surgery of STS in the lower limb between January 1988 and December 2003.
  • Blood vessel involvement by STS was classified as follows: type I, artery and vein; type II, artery only; type III, vein only; and type IV, neither artery nor vein (excluded from the analysis).
  • RESULTS: Twenty-one (9.9%) of 213 patients underwent vascular resections for lower limb STS.
  • Besides 17 type I tumors (81.0%), 3 (14.3%) type II and 1 (4.7%) type III STS were diagnosed.
  • CONCLUSIONS: Long-term bypass patency rates, the high percentage of limb salvage, and the oncologic outcome underline the efficacy of en bloc resection of STS involving major vessels in the lower limb.
  • [MeSH-major] Blood Vessel Prosthesis Implantation. Limb Salvage. Sarcoma / surgery. Vascular Neoplasms / surgery

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012457.001).
  • [ISSN] 0741-5214
  • [Journal-full-title] Journal of vascular surgery
  • [ISO-abbreviation] J. Vasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Polyethylene Terephthalates; 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


49. Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miyagi T, Maeda Y, Kitagawa Y, Kadono Y, Konaka H, Namiki M: Role of surgical resection in adult urological soft tissue sarcoma: 25-year experience. Urol Int; 2010;84(3):309-14
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of surgical resection in adult urological soft tissue sarcoma: 25-year experience.
  • INTRODUCTION: As adult urological soft tissue sarcomas (STS) are rare, there have been few recent large-scale studies of these tumors.
  • This report describes a single institutional experience of adult urological STS over 25 years.
  • PATIENTS AND METHODS: The study population consisted of 25 adult patients with histologically diagnosed STS arising in the urinary tract, male genital system, or retroperitoneum between January 1983 and July 2008.
  • CONCLUSIONS: Surgical resection, regardless of status of surgical resection margin, contributed to a favorable prognosis in adult patients with locally advanced or metastatic urological STS.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery. Urologic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20389161.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


50. Ristovska G, Gjorgjev D, Polozhani A, Kocubovski M, Kendrovski V: Environmental noise and annoyance in adult population of Skopje: a cross-sectional study. Arh Hig Rada Toksikol; 2009 Sep;60(3):349-55
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Environmental noise and annoyance in adult population of Skopje: a cross-sectional study.
  • We have performed noise measurements and interviewed 510 adult subjects, using a questionnaire, prepared according to the ISO/TS-15666 standard.
  • [MeSH-minor] Adult. Female. Humans. Macedonia (Republic). Male

  • MedlinePlus Health Information. consumer health - Noise.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789165.001).
  • [ISSN] 0004-1254
  • [Journal-full-title] Arhiv za higijenu rada i toksikologiju
  • [ISO-abbreviation] Arh Hig Rada Toksikol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


51. Li J, Wang Z, Shi D, Chen Y: Adult exposure to sasanguasaponin induces spermatogenic cell apoptosis in vivo through increased oxidative stress in male mice. Toxicol Ind Health; 2010 Nov;26(10):691-700

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult exposure to sasanguasaponin induces spermatogenic cell apoptosis in vivo through increased oxidative stress in male mice.
  • Effects of sasanguasaponin (SGS), a compound from defatted seeds of Camellia oleifera, on abnormal spermatogenesis were studied in adult male mice using daily intragastric administration of 100, 200 and 400 mg/kg body weight (BW) for 6 weeks.
  • Germ cells were rarefied and showed irregular distribution in seminiferous tubules (STs).
  • These results suggest that adult exposure to SGS (400 mg/kg) induces spermatogenic apoptosis through increased oxidative stress in male mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627992.001).
  • [ISSN] 1477-0393
  • [Journal-full-title] Toxicology and industrial health
  • [ISO-abbreviation] Toxicol Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 22-O-angeloylcamelliagenin C-3-O-(glucopyranosyl-1-2)(glucopyranosyl-1-2-O-arabinopyranosyl-1-3-)glucopyranosiduronic acid; 0 / Drugs, Chinese Herbal; 0 / Saponins
  •  go-up   go-down


52. Putman LM, van Gameren M, Meijboom FJ, de Jong PL, Roos-Hesselink JW, Witsenburg M, Takkenberg JJ, Bogers AJ: Seventeen years of adult congenital heart surgery: a single centre experience. Eur J Cardiothorac Surg; 2009 Jul;36(1):96-104; discussion 104
MedlinePlus Health Information. consumer health - Congenital Heart Defects.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seventeen years of adult congenital heart surgery: a single centre experience.
  • METHODS: Patients and operative characteristics of all consecutive adult CHD patients operated upon between January 1990 and January 2007 were collected.
  • Categorisation was done according to the EACTS/STS congenital database.
  • CONCLUSIONS: Surgery in adult CHD patients can be performed with low operative mortality and good clinical outcome.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Length of Stay / statistics & numerical data. Male. Middle Aged. Postoperative Complications. Prognosis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303791.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Almeida PS, Manoel WJ, Reis AA, Silva ER, Martins E, Paiva MV, Fraga AC Jr, Saddi VA: TP53 codon 72 polymorphism in adult soft tissue sarcomas. Genet Mol Res; 2008;7(4):1344-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 codon 72 polymorphism in adult soft tissue sarcomas.
  • Soft tissue sarcomas (STS) are tumors of mesodermal origin, comprising about 1% of all adult neoplasms.
  • We investigated p53 codon 72 polymorphism (Arg72Pro) frequencies with respect to the susceptibility and the clinical outcome of patients with STS.
  • A series of 100 STS were genotyped for the p53 Arg72Pro polymorphism using polymerase chain reaction.
  • Possible associations between polymorphic genotypes, clinicopathological factors and survival of STS patients were also investigated.
  • Genotypic frequencies obtained for STS patients did not significantly differ from that obtained for controls.
  • In the STS group, p53 codon 72 polymorphic variants were not significantly associated with gender, age, tumor size, clinical stage, tumor grade, histology, or nodal or distant metastasis.
  • The five-year overall survival rate for the STS group was 48%; it was significantly affected by tumor grade, clinical stage, and nodal and distant metastasis.
  • Soft tissue sarcoma patients with the Pro/Pro variant had a reduced survival rate (30%), when compared to the p53 Arg/Arg (45%) and the p53 Arg/Pro groups (55%).
  • [MeSH-major] Codon / genetics. Polymorphism, Genetic. Sarcoma / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arginine / genetics. Female. Gene Frequency. Genes, p53. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Proline / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065769.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Codon; 0 / Tumor Suppressor Protein p53; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline
  •  go-up   go-down


54. Kopp HG, Patel S, Brücher B, Hartmann JT: Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. Am J Clin Dermatol; 2008;9(4):207-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
  • Soft-tissue sarcomas (STS) include a spectrum of histologically and clinically different tumors.
  • We summarize current treatment options for metastatic STS, including established first-line chemotherapy approaches, mainly with anthracyclines and/or ifosfamide and second-line treatment choices beyond anthracyclines.
  • Until only a few years ago, treatment choices for metastatic STS were easy to review because of the very limited number of active compounds available.
  • However, with the advent of novel therapeutic strategies such as the anti-angiogenic approach and a multitude of novel compounds available both outside and within clinical studies, it has potentially become more difficult to keep track of currently available treatment options for STS and their clinical safety and efficacy.
  • In this practice-oriented article, we therefore review treatment goals in advanced STS and provide an overview of compounds with proven activity in this setting.
  • Anthracyclines with or without ifosfamide are still considered standard of care for most STS subtypes, especially for high-grade tumors.
  • Recently, trabectedin, a DNA minor groove binder initially isolated from a sea sponge, has proven effective and received European approval for use in treatment-refractory STS.
  • In order to be successful, it may be necessary to combine not only different compounds but also different targets beyond the proliferation machinery of sarcoma cells such as tumor angiogenesis, the tumor stromal compartment, or tumor cell oncogene products.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / administration & dosage. Anthracyclines / administration & dosage. Antibodies, Monoclonal / administration & dosage. Humans. Neoplasm Staging. Protein Kinase Inhibitors / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18572972.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Protein Kinase Inhibitors
  • [Number-of-references] 108
  •  go-up   go-down


55. Engelhardt M, Zeiser R, Ihorst G, Finke J, Müller CI: High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patients with high-risk or advanced Ewing and soft tissue sarcoma. J Cancer Res Clin Oncol; 2007 Jan;133(1):1-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patients with high-risk or advanced Ewing and soft tissue sarcoma.
  • PURPOSE: Despite the availability of combined-modality treatment for Ewing sarcoma (ES) and soft tissue sarcomas (STS), results from independent groups still indicate a poor prognosis for high-risk and metastasized patients.
  • METHODS: Here, we report of HDCT in 35 consecutive adult patients with poor-risk ES or rhabdomyosarcoma (n = 11) and STS (n = 24) undergoing ASCT between July 1992 and March 2003.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peripheral Blood Stem Cell Transplantation. Sarcoma / therapy. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Prognosis. Prospective Studies. Rhabdomyosarcoma / therapy. Risk Factors. Survival Analysis. Transplantation, Autologous. Treatment Outcome


56. Gammie JS, Zhao Y, Peterson ED, O'Brien SM, Rankin JS, Griffith BP: J. Maxwell Chamberlain Memorial Paper for adult cardiac surgery. Less-invasive mitral valve operations: trends and outcomes from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg; 2010 Nov;90(5):1401-8, 1410.e1; discussion 1408-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] J. Maxwell Chamberlain Memorial Paper for adult cardiac surgery. Less-invasive mitral valve operations: trends and outcomes from the Society of Thoracic Surgeons Adult Cardiac Surgery Database.
  • METHODS: Between 2004 and 2008, 28,143 patients undergoing isolated mitral valve (MV) operations were identified in The Society of Thoracic Surgeons Adult Cardiac Surgical Database (STS ACSD).
  • In 2008, 26% of STS ACSD centers performed at least one LIMV operation, with a median of 3 per year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20971230.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


57. Gammie JS, Sheng S, Griffith BP, Peterson ED, Rankin JS, O'Brien SM, Brown JM: Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg; 2009 May;87(5):1431-7; discussion 1437-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database.
  • BACKGROUND: The purpose of this study is to examine trends in mitral valve (MV) repair and replacement surgery using The Society of Thoracic Surgeons Adult Cardiac Surgery Database (STS ACSD).
  • METHODS: The study population included isolated mitral valve operations performed between January 2000 and December 2007 at 910 hospitals participating in the STS ACSD.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Databases, Factual. Female. Heart Valve Diseases / surgery. Humans. Male. Middle Aged. Patient Selection. Regression Analysis. Risk Factors. Societies, Medical. Survival Rate. Survivors. Treatment Outcome. United States

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379881.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


58. Jacobs JP, Edwards FH, Shahian DM, Haan CK, Puskas JD, Morales DL, Gammie JS, Sanchez JA, Brennan JM, O'Brien SM, Dokholyan RS, Hammill BG, Curtis LH, Peterson ED, Badhwar V, George KM, Mayer JE Jr, Chitwood WR Jr, Murray GF, Grover FL: Successful linking of the Society of Thoracic Surgeons adult cardiac surgery database to Centers for Medicare and Medicaid Services Medicare data. Ann Thorac Surg; 2010 Oct;90(4):1150-6; discussion 1156-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful linking of the Society of Thoracic Surgeons adult cardiac surgery database to Centers for Medicare and Medicaid Services Medicare data.
  • BACKGROUND: The Centers for Medicare and Medicaid Services (CMS) Medicare database complements The Society of Thoracic Surgeons (STS) database by providing information about long-term outcomes and cost.
  • This study demonstrates the feasibility of linking STS data to CMS data and examines the penetration, completeness, and representativeness of the STS database.
  • METHODS: Using variables common to both STS and CMS databases, STS operations were linked to CMS data for all CMS coronary artery bypass graft surgery (CABG) hospitalizations discharged between 2000 and 2007, inclusive.
  • For each CMS CABG hospitalization, it was determined whether a matching STS record existed.
  • RESULTS: Center-level penetration (number of CMS sites with at least one matched STS participant divided by the total number of CMS CABG sites) increased from 45% to 78%.
  • In 2007, 854 of 1,101 CMS CABG sites (78%) were linked to an STS site.
  • Patient-level penetration (number of CMS CABG hospitalizations done at STS sites divided by the total number of CMS CABG hospitalizations) increased from 51% to 84%.
  • In 2007, 94,409 of 111,967 CMS CABG hospitalizations (84%) were at an STS site.
  • Completeness of case inclusion at STS sites (number of CMS CABG cases at STS sites linked to STS records divided by the total number of CMS CABG cases at STS sites) increased from 88% to 97%.
  • In 2007, 88,857 of 91,363 CMS CABG hospitalizations at STS sites (97%) were linked to an STS record.
  • CONCLUSIONS: The successful linking of STS and CMS databases demonstrates high and increasing penetration and completeness of the STS database.
  • Linking STS and CMS data will facilitate studying long-term outcomes of cardiothoracic surgery.
  • [MeSH-minor] Adult. Algorithms. Centers for Medicare and Medicaid Services (U.S.). Feasibility Studies. Humans. Societies, Medical. Treatment Outcome. United States

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Ann Thorac Surg. 2010 Oct;90(4):1065-6 [20868787.001]
  • (PMID = 20868806.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


59. Akita K, von Holst A, Furukawa Y, Mikami T, Sugahara K, Faissner A: Expression of multiple chondroitin/dermatan sulfotransferases in the neurogenic regions of the embryonic and adult central nervous system implies that complex chondroitin sulfates have a role in neural stem cell maintenance. Stem Cells; 2008 Mar;26(3):798-809
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multiple chondroitin/dermatan sulfotransferases in the neurogenic regions of the embryonic and adult central nervous system implies that complex chondroitin sulfates have a role in neural stem cell maintenance.
  • Chondroitin/dermatan sulfotransferases (C/D-STs) underlie the synthesis of diverse sulfated structures in chondroitin/dermatan sulfate (CS/DS) chains.
  • Here, we examined the gene expression profile of C/D-STs in the neurogenic regions of embryonic and adult mouse central nervous system.
  • Using reverse transcription-polymerase chain reaction analysis, all presently known C/D-STs were detected in the dorsal and ventral telencephalon of the embryonic day 13 (E13) mouse embryo, with the exception of chondroitin 4-O-sulfotransferase (C4ST)-3.
  • The expression of multiple C/D-STs is maintained on cells residing in the adult neural stem cell niche.
  • Consistent with the gene expression pattern of C/D-STs, disaccharide analysis revealed that neurospheres and E13 mouse brain cells synthesized CS/DS chains containing monosulfated, but also significant amounts of disulfated, disaccharide units.
  • The synergistic activities of C/D-STs might allow for the adaptive modification of CS/DS proteoglycans with diversely sulfated CS/DS chains in the extracellular microenvironment that surrounds neural stem cells.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. SODIUM CHLORATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079434.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chlorates; 0 / Culture Media, Conditioned; 0 / Disaccharides; 0 / Epitopes; 0 / Protein Isoforms; 24967-94-0 / Dermatan Sulfate; 9007-28-7 / Chondroitin Sulfates; EC 2.8.2.- / Sulfotransferases; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 5; T95DR77GMR / sodium chlorate
  •  go-up   go-down


60. Hartmann JT, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C: An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs; 2006 May;24(3):249-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.
  • BACKGROUND: The number of effective cytotoxic agents for the treatment of patients with metastatic adult type soft tissue sarcoma (STS) is limited, when patients have failed anthracyline-based chemotherapy.
  • CONCLUSIONS: Considering response and progression-free rate as the primary endpoints for phase II trials in pretreated STS, gemcitabine has moderate efficacy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1329-34 [11870176.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):644-7 [14766260.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2261-9 [15484216.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1248-55 [11230465.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Anticancer Drugs. 2000 Jun;11(5):325-9 [10912948.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1899-901 [12820475.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1969-73 [12673725.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(2):177-81 [10663634.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2248-52 [8635028.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3225-9 [12115355.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1634-9 [9862576.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S174-9 [8453693.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1296-7 [9849496.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):422-3 [9640234.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • (PMID = 16133789.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


61. Choi J, Curtis SJ, Roy DM, Flesken-Nikitin A, Nikitin AY: Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency. Am J Pathol; 2010 Nov;177(5):2645-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency.
  • The cell of origin and pathogenesis of the majority of adult soft tissue sarcomas (STS) remains poorly understood.
  • Because mutations in both the P53 and RB tumor suppressor genes are frequent in STS in humans, we inactivated these genes by Cre-loxP-mediated recombination in mice with floxed p53 and Rb.
  • Similar to human STS, these sarcomas overexpress Cxcr4, which contributes to their invasive properties.
  • At the same time, dermal mesenchymal stem cells isolated by strict plastic adherence and low levels of Sca-1 expression (Sca-1low, CD31negCD45neg) have shown enhanced potential for malignant transformation according to soft agar, invasion, and tumorigenicity assays, after the conditional inactivation of both p53 and Rb.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 1989 Sep;1(1):9-14 [2562116.001]
  • [Cites] Exp Mol Pathol. 1991 Feb;54(1):61-71 [1847338.001]
  • [Cites] Jpn J Cancer Res. 1991 Mar;82(3):298-307 [1850724.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8433-8 [17823410.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):791-9 [17851544.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3248-57 [17948129.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2007;2007:5830-33 [18003339.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10889-98 [18006834.001]
  • [Cites] J Biomed Opt. 2007 Nov-Dec;12(6):064007 [18163823.001]
  • [Cites] Clin Exp Metastasis. 2008;25(1):1-10 [17768666.001]
  • [Cites] Carcinogenesis. 2008 Mar;29(3):620-8 [17893233.001]
  • [Cites] Genes Dev. 2008 Jun 15;22(12):1662-76 [18559481.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11851-6 [18697945.001]
  • [Cites] Cell Stem Cell. 2008 Nov 6;3(5):475-9 [18983962.001]
  • [Cites] Carcinogenesis. 2009 Jan;30(1):150-7 [18849298.001]
  • [Cites] Int J Cancer. 2009 Apr 15;124(8):1852-9 [19107931.001]
  • [Cites] Neoplasia. 2009 Apr;11(4):397-407 [19308294.001]
  • [Cites] Cell Stem Cell. 2009 Apr 3;4(4):301-12 [19341620.001]
  • [Cites] Cell Stem Cell. 2009 Apr 3;4(4):336-47 [19341623.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Semin Oncol. 2009 Aug;36(4):324-37 [19664493.001]
  • [Cites] Carcinogenesis. 2009 Oct;30(10):1789-95 [19635748.001]
  • [Cites] Clin Cancer Res. 2010 Feb 15;16(4):1119-28 [20145172.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jun;136(6):829-38 [19936790.001]
  • [Cites] Virchows Arch. 2010 Feb;456(2):201-17 [20217954.001]
  • [Cites] Development. 2000 Apr;127(8):1607-16 [10725237.001]
  • [Cites] Cell Growth Differ. 1991 Oct;2(10):495-501 [1661131.001]
  • [Cites] Am J Clin Pathol. 1992 Jun;97(6):759-63 [1317667.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(3):151-9 [7902172.001]
  • [Cites] Lab Invest. 1995 Jun;72(6):679-88 [7783426.001]
  • [Cites] Semin Diagn Pathol. 1995 Aug;12(3):210-20 [8545588.001]
  • [Cites] Mech Dev. 1998 Aug;76(1-2):79-90 [9867352.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jun;111(2):134-8 [10347550.001]
  • [Cites] Cancer. 1961 May-Jun;14:469-82 [13751857.001]
  • [Cites] Cancer. 1963 Mar;16:331-44 [13940913.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1835-41 [15756007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6942-7 [15860580.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2181-7 [16489019.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] Mod Pathol. 2006 May;19(5):738-45 [16528367.001]
  • [Cites] Nature. 2006 Apr 27;440(7088):1199-203 [16565704.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7889-98 [16912162.001]
  • [Cites] Oncogene. 2006 Aug 28;25(38):5250-6 [16936744.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]
  • [Cites] Oncogene. 2007 May 17;26(23):3329-37 [17130833.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5683-90 [17553900.001]
  • [Cites] Nat Med. 2007 Aug;13(8):992-7 [17676052.001]
  • [Cites] Development. 2000 Apr;127(8):1671-9 [10725243.001]
  • [Cites] Genes Dev. 2000 Apr 15;14(8):994-1004 [10783170.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1034-8 [10871752.001]
  • [Cites] Genesis. 2000 Nov-Dec;28(3-4):147-55 [11105057.001]
  • [Cites] Lab Invest. 2001 Feb;81(2):211-5 [11232643.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] Biotechniques. 2002 Mar;32(3):548-51 [11911658.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Dev Biol. 2002 May 1;245(1):42-56 [11969254.001]
  • [Cites] J Biomed Mater Res. 2002 Dec 15;62(4):499-506 [12221697.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):175-8 [12242149.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12):843-9 [12476275.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3459-63 [12839925.001]
  • [Cites] Int J Oncol. 2003 Aug;23(2):343-51 [12851683.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Stem Cells. 2003;21(5):527-35 [12968107.001]
  • [Cites] Br J Haematol. 2003 Nov;123(4):702-11 [14616976.001]
  • [Cites] Cancer. 2004 May 15;100(10):2233-9 [15139069.001]
  • [Cites] Ann N Y Acad Sci. 2004 May;1015:182-9 [15201159.001]
  • [Cites] Cell. 2004 Aug 20;118(4):409-18 [15315754.001]
  • [Cites] Radiat Res. 1970 Apr;42(1):151-63 [4908603.001]
  • [Cites] Cancer. 1975 Jan;35(1):176-98 [162851.001]
  • [Cites] Acta Pathol Jpn. 1980 Sep;30(5):767-78 [6255737.001]
  • [Cites] Hum Pathol. 1983 Oct;14(10):913-22 [6311725.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2521-32 [2986815.001]
  • [Cites] Am J Pathol. 1986 Aug;124(2):303-9 [2426951.001]
  • [Cites] Am J Pathol. 1986 Oct;125(1):113-23 [3490790.001]
  • [Cites] Acta Pathol Jpn. 1987 Jun;37(6):975-88 [2820186.001]
  • [Cites] J Cancer Res Clin Oncol. 1987;113(6):559-62 [2824521.001]
  • [Cites] Arch Dermatol. 1988 Mar;124(3):319-21 [3257856.001]
  • [Cites] Pathol Res Pract. 1988 Nov;183(6):698-705 [2851775.001]
  • [Cites] Lab Invest. 1990 May;62(5):635-45 [2160564.001]
  • [Cites] Oncogene. 1990 Sep;5(9):1297-301 [2216456.001]
  • (PMID = 20864684.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / K26 RR017595; United States / PHS HHS / / C023050; United States / NCI NIH HHS / CA / R56 CA096823; United States / NCRR NIH HHS / RR / RR17595; United States / NCI NIH HHS / CA / R01 CA096823; United States / NCI NIH HHS / CA / CA96823
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2966819
  •  go-up   go-down


62. Fernebro J, Carneiro A, Rydholm A, Domanski HA, Karlsson A, Borg A, Nilbert M: Genetic profiling differentiates second primary tumors from metastases in adult metachronous soft tissue sarcoma. Sarcoma; 2008;2008:431019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic profiling differentiates second primary tumors from metastases in adult metachronous soft tissue sarcoma.
  • Purpose. Patients with soft tissue sarcomas (STS) are at increased risk of second primary malignancies, including a second STS, but distinction between metastases and a second primary STS is difficult.
  • Array-based comparative genomic hybridization (aCGH) was applied to 30 multiple STS of the extremities and the trunk wall from 13 patients.
  • In an unsupervised hierarchical cluster analysis, similar genomic profiles and close clustering between the first and subsequent STS were identified in 5 cases, suggesting metastatic disease, whereas the tumors from the remaining 8 patients did not cluster and showed only weak pairwise correlation, suggesting development of second primary STS.
  • Discussion. The similarities and dissimilarities identified in the first and second STS suggest that genetic profiles can be used to distinguish soft tissue metastases from second primary STS.
  • The demonstration of genetically different soft tissue sarcomas in the same patient suggests independent tumor origin and serves as a reminder to consider development of second primary STS, which has prognostic and therapeutic implications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmic Genet. 1997 Mar;18(1):27-34 [9134547.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):960-5 [9307198.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1851-9 [7636528.001]
  • [Cites] Clin Exp Metastasis. 1993 Sep;11(5):401-8 [8375115.001]
  • [Cites] Ann Surg. 1993 Jan;217(1):72-7 [8424704.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):262-70 [8426203.001]
  • [Cites] Acta Orthop Scand. 1992 Feb;63(1):98-9 [1738982.001]
  • [Cites] Jpn J Surg. 1986 Jul;16(4):277-83 [3773360.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1758-65 [15073867.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 1;150(1):27-32 [15041220.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):357-63 [14996857.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1947-57 [14584079.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1619-30 [11822764.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):1-12 [11752241.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):978-84 [11598167.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1363-71 [11283938.001]
  • [Cites] Lab Invest. 2001 Feb;81(2):211-5 [11232643.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2788-93 [10914725.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8984-93 [16982739.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):986-90 [17008869.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jun;119(2):102-8 [10867143.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Sep;169(2):94-101 [16938566.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):476-83 [16421424.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):545-51 [16125217.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Oct;27(10):517-20 [16217253.001]
  • [Cites] Jpn J Clin Oncol. 2005 Aug;35(8):444-52 [16024533.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2391-6 [15852362.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2272-9 [15800318.001]
  • [Cites] Virchows Arch. 2005 Mar;446(3):251-8 [15731925.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):591-7 [15696129.001]
  • [Cites] Bioinformatics. 2003 Sep 1;19(13):1714-5 [15593402.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2633-5 [15494976.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):323-31 [10398425.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):985-90 [9736047.001]
  • [Cites] Ann Surg Oncol. 1998 Jan-Feb;5(1):37-40 [9524706.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):603-9 [7884422.001]
  • (PMID = 19197386.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2634844
  •  go-up   go-down


63. Liakakos TD, Troupis TG, Tzathas C, Spirou K, Nikolaou I, Ladas S, Karatzas GM: Primary liposarcoma of esophagus: a case report. World J Gastroenterol; 2006 Feb 21;12(7):1149-52
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposarcoma is the most common soft tissue sarcoma in adult life while esophageal liposarcoma is an extremely rare tumor.

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Imaging. 1999 Oct;14(4):316-9 [10524816.001]
  • [Cites] Can J Gastroenterol. 2002 Jun;16(6):377-9 [12096301.001]
  • [Cites] Yonsei Med J. 2003 Aug 30;44(4):715-8 [12950130.001]
  • [Cites] J Am Coll Surg. 2004 Feb;198(2):320-1 [14964253.001]
  • [Cites] Arch Pathol Lab Med. 2004 Aug;128(8):922-5 [15270604.001]
  • [Cites] J Thorac Cardiovasc Surg. 1983 Sep;86(3):447-50 [6887958.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Aug;116(2):365-7 [9699597.001]
  • [Cites] Korean J Intern Med. 1989 Jan;4(1):86-9 [2487410.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):1012-3 [2039300.001]
  • [Cites] Eur J Surg Oncol. 1991 Jun;17(3):313-5 [2044787.001]
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):398-407 [9164509.001]
  • [Cites] Dis Esophagus. 1998 Jan;11(1):68-71 [9595239.001]
  • [Cites] Clin Radiol. 1990 Nov;42(5):356-8 [2245576.001]
  • (PMID = 16534863.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087914
  •  go-up   go-down


64. Motomura N, Miyata H, Tsukihara H, Takamoto S, Japan Cardiovascular Surgery Database Organization: Risk model of valve surgery in Japan using the Japan Adult Cardiovascular Surgery Database. J Heart Valve Dis; 2010 Nov;19(6):684-91
MedlinePlus Health Information. consumer health - Heart Valve Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk model of valve surgery in Japan using the Japan Adult Cardiovascular Surgery Database.
  • The study aim was to collect Japanese data and to prepare a risk stratification of cardiac valve procedures, using the Japan Adult Cardiovascular Surgery Database (JACVSD).
  • The performance of this risk model also matched that of the STS National Adult Cardiac Database and the European Society Database.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21214090.001).
  • [ISSN] 0966-8519
  • [Journal-full-title] The Journal of heart valve disease
  • [ISO-abbreviation] J. Heart Valve Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, Sikic BI: Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol; 2007 Apr 10;25(11):1341-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.
  • PATIENTS AND METHODS: DNA microarrays were used to profile a set of 54 adult ALL specimens from the Medical Research Council UKALL XII/Eastern Cooperative Oncology Group E2993 trial (21 p185BCR-ABL-positive, 16 p210BCR-ABL-positive and 17 BCR-ABL-negative specimens).
  • RESULTS: Using supervised and unsupervised analysis tools, we detected significant transcriptomic changes in BCR-ABL-positive versus -negative specimens, and assessed their validity in an independent cohort of 128 adult ALL specimens.
  • Within the BCR-ABL-positive subgroups, we identified genes overexpressed (PILRB, STS-1, SPRY1) or underexpressed (TSPAN16, ADAMTSL4) in p185BCR-ABL-positive ALL relative to p210BCR-ABL-positive ALL.
  • Finally, we constructed a gene expression- and interaction-based outcome predictor consisting of 27 genes (including GRB2, GAB1, GLI1, IRS1, RUNX2, and SPP1), which correlated with overall survival in BCR-ABL-positive adult ALL (P = .0001), independent of age (P = .25) and WBC count at presentation (P = .003).
  • CONCLUSION: We identified prominent molecular features of BCR-ABL-positive adult ALL, which may be useful for developing novel therapeutic targets and prognostic markers in this disease.
  • [MeSH-minor] Adult. Gene Expression Profiling. Humans. Oligonucleotide Array Sequence Analysis. Proportional Hazards Models. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Survival Analysis


66. Swallow CJ, Catton CN: Local management of adult soft tissue sarcomas. Semin Oncol; 2007 Jun;34(3):256-69
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local management of adult soft tissue sarcomas.
  • Soft tissue sarcomas (STS) are rare tumors classified into multiple histological subtypes and categorized into four sites: extremity and trunk, head and neck, retroperitoneal, and visceral, the latter now predominantly consisting of gastrointestinal stromal tumors.
  • This planning is most expeditiously done through multidisciplinary consultation at an experienced sarcoma center.
  • [MeSH-major] Sarcoma / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Limb Salvage. Prognosis. Radiotherapy, Adjuvant. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560988.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 79
  •  go-up   go-down


67. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY: Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer; 2010 Jan;46(1):72-83
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
  • BACKGROUND: Adult patients with advanced soft tissue sarcomas (STS) are generally treated similarly, regardless of great differences between STS subtypes, disease presentation and patients' characteristics.
  • METHODS: A retrospective, exploratory analysis was performed on data from 1337 advanced STS patients who received first-line ifosfamide-containing chemotherapy.
  • RESULTS: Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma.
  • For response, independent favourable prognostic factors were doxorubicin combined with ifosfamide, higher histological grade, and histology with synovial sarcoma patients having the highest chance to respond.
  • CONCLUSION: In this study, we established an independent set of prognostic and predictive factors for outcome to ifosfamide-based chemotherapy in advanced STS patients.
  • This study provides important information for the interpretation and design of clinical trials for specific STS entities and may contribute to further treatment individualisation of advanced STS patients.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Ifosfamide / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy


68. Mateos-Hernandez M, Singh RP, Hulbert SH, Bowden RL, Huerta-Espino J, Gill BS, Brown-Guedira G: Targeted mapping of ESTs linked to the adult plant resistance gene Lr46 in wheat using synteny with rice. Funct Integr Genomics; 2006 Apr;6(2):122-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted mapping of ESTs linked to the adult plant resistance gene Lr46 in wheat using synteny with rice.
  • Wheat expressed sequence tags (ESTs) mapping in the terminal 15% of chromosome 1BL with significant homology to sequences from the terminal region of chromosome 5L of rice were chosen for sequence-tagged site (STS) primer design and were mapped physically and genetically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hereditas. 2001;135(2-3):111-4 [12152322.001]
  • [Cites] Funct Integr Genomics. 2004 Mar;4(1):59-66 [14752608.001]
  • [Cites] Genome. 2003 Oct;46(5):817-23 [14608398.001]
  • [Cites] Phytopathology. 2003 Feb;93(2):153-9 [18943129.001]
  • [Cites] Phytopathology. 2003 Jul;93(7):881-90 [18943170.001]
  • [Cites] Cell. 1997 Mar 7;88(5):695-705 [9054509.001]
  • [Cites] Funct Integr Genomics. 2004 Mar;4(1):47-58 [14767678.001]
  • [Cites] Genetics. 2004 Oct;168(2):701-12 [15514046.001]
  • [Cites] Phytopathology. 1997 Mar;87(3):236-41 [18945165.001]
  • [Cites] Phytopathology. 1998 Sep;88(9):890-4 [18944865.001]
  • [Cites] Genetics. 2004 Oct;168(2):609-23 [15514039.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 07;32(12):3546-65 [15240829.001]
  • [Cites] Genome. 1993 Apr;36(2):289-93 [18469988.001]
  • [Cites] Plant Cell. 1996 Jan;8(1):5-14 [12239354.001]
  • [Cites] Annu Rev Phytopathol. 1996;34:435-55 [15012551.001]
  • [Cites] Funct Integr Genomics. 2003 Mar;3(1-2):39-55 [12590342.001]
  • [Cites] Genetics. 2003 Jun;164(2):673-83 [12807788.001]
  • [Cites] Funct Integr Genomics. 2004 Mar;4(1):34-46 [14740255.001]
  • [Cites] Anal Biochem. 1991 Jul;196(1):80-3 [1716076.001]
  • [Cites] Funct Integr Genomics. 2004 May;4(2):74-83 [15015127.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • (PMID = 16374594.001).
  • [ISSN] 1438-793X
  • [Journal-full-title] Functional & integrative genomics
  • [ISO-abbreviation] Funct. Integr. Genomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


69. Mocellin S, Rossi CR, Brandes A, Nitti D: Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev; 2006 Feb;32(1):9-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches.
  • The therapeutic approach to soft tissue sarcomas (STS) has evolved over the past two decades based on the results from randomized controlled trials, which are guiding physicians in the treatment decision-making process.
  • In addition, the characteristic chemoresistance of STS has compromised the therapeutic value of conventional antineoplastic agents in cases of unresectable advanced/metastatic disease.
  • Therefore, novel therapeutic strategies are urgently needed to improve the prognosis of patients with STS.
  • Recent advances in STS biology are paving the way to the development of molecularly targeted therapeutic strategies, the efficacy of which relies not only on the knowledge of the molecular mechanisms underlying cancer development/progression but also on the personalization of the therapeutic regimen according to the molecular features of individual tumours.
  • In this work, we review the state-of-the-art of conventional treatments for STS and summarize the most promising findings in the development of molecularly targeted therapeutic approaches.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Sarcoma / metabolism. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant. Enzyme Inhibitors / therapeutic use. Genetic Therapy. Growth Substances / metabolism. Humans. Matrix Metalloproteinase Inhibitors. Middle Aged. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338075.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Cancer Vaccines; 0 / Enzyme Inhibitors; 0 / Growth Substances; 0 / Matrix Metalloproteinase Inhibitors
  • [Number-of-references] 234
  •  go-up   go-down


70. Santra DK, Chen XM, Santra M, Campbell KG, Kidwell KK: Identification and mapping QTL for high-temperature adult-plant resistance to stripe rust in winter wheat (Triticum aestivum L.) cultivar 'Stephens'. Theor Appl Genet; 2008 Sep;117(5):793-802

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and mapping QTL for high-temperature adult-plant resistance to stripe rust in winter wheat (Triticum aestivum L.) cultivar 'Stephens'.
  • High-temperature adult-plant (HTAP) resistance from the winter wheat (Triticum aestivum) cultivar 'Stephens' has protected wheat crops from stripe rust caused by Puccinia striiformis f. sp. tritici for 30 years.
  • The 101 F(8) RILs were evaluated with 250 resistance gene analog polymorphism (RGAP), 245 simple sequence repeat (SSR) and 1 sequence tagged site (STS) markers for genetic linkage map construction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Phytopathol. 2002;40:75-118 [12147755.001]
  • [Cites] Funct Integr Genomics. 2004 Mar;4(1):59-66 [14752608.001]
  • [Cites] Theor Appl Genet. 2005 May;110(8):1401-9 [15841362.001]
  • [Cites] Theor Appl Genet. 2005 Nov;111(7):1260-70 [16179997.001]
  • [Cites] Genetics. 1998 May;149(1):383-403 [9584111.001]
  • [Cites] Phytopathology. 2003 Jul;93(7):881-90 [18943170.001]
  • [Cites] Theor Appl Genet. 1992 May;83(8):1035-43 [24202932.001]
  • [Cites] Genetics. 1989 Jan;121(1):185-99 [2563713.001]
  • [Cites] Genomics. 1987 Oct;1(2):174-81 [3692487.001]
  • [Cites] Theor Appl Genet. 2005 Dec;112(1):97-105 [16208504.001]
  • [Cites] Genomics. 1995 Dec 10;30(3):450-8 [8825630.001]
  • [Cites] Theor Appl Genet. 2007 May;114(7):1277-87 [17318493.001]
  • [Cites] Theor Appl Genet. 2005 Feb;110(3):550-60 [15655666.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10972-6 [8248199.001]
  • [Cites] Genetics. 2004 May;167(1):485-98 [15166171.001]
  • [Cites] Funct Integr Genomics. 2003 Mar;3(1-2):39-55 [12590342.001]
  • [Cites] Genetics. 1998 Aug;149(4):2007-23 [9691054.001]
  • [Cites] Genetics. 1994 Apr;136(4):1457-68 [8013918.001]
  • [Cites] Theor Appl Genet. 2004 Oct;109(6):1105-14 [15490101.001]
  • [Cites] Genome. 2001 Aug;44(4):509-16 [11550883.001]
  • (PMID = 18584147.001).
  • [ISSN] 0040-5752
  • [Journal-full-title] TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik
  • [ISO-abbreviation] Theor. Appl. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


71. Bauer S, Hartmann JT: Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors. Crit Rev Oncol Hematol; 2006 Nov;60(2):112-30
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors.
  • STS belong to the most challenging diseases in oncology that demand all resources of modern clinical oncology.
  • For patients with metastatic sarcoma long-term survival can only be achieved in a small number of patients with mostly resectable disease.
  • A variety of new drugs or drug combinations seem to exhibit considerable activity in certain histological sarcoma subtypes, which may soon broaden the armamentarium of drugs for a subset of patients.
  • However, with the vastly improved understanding of the biology and pathology of soft tissue sarcoma an era of opportunities seems to have begun and the recent success in the treatment of gastrointestinal stromal tumors impressively shows how fast a gain in the understanding of oncogenic mechanisms may translate into a highly efficient, clinically useful treatment.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / radiotherapy. Sarcoma / drug therapy. Sarcoma / radiotherapy

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949832.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 138
  •  go-up   go-down


72. Weber DC, Rutz HP, Bolsi A, Pedroni E, Coray A, Jermann M, Lomax AJ, Hug EB, Goitein G: Spot scanning proton therapy in the curative treatment of adult patients with sarcoma: the Paul Scherrer institute experience. Int J Radiat Oncol Biol Phys; 2007 Nov 1;69(3):865-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spot scanning proton therapy in the curative treatment of adult patients with sarcoma: the Paul Scherrer institute experience.
  • PURPOSE: To assess the safety and efficacy of spot scanning proton beam therapy (PT) in the curative treatment of soft-tissue sarcoma (STS) in adults patients.
  • PATIENTS AND METHODS: We identified 13 STS patients treated with PT between July 1998 and May 2005 in our institutional database.
  • CONCLUSIONS: Spot scanning PT is an effective and safe treatment for patient with STS in critical locations.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Protons / therapeutic use. Sarcoma / radiotherapy
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant / adverse effects. Switzerland. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606333.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


73. Poveda A, López-Pousa A, Martín J, Del Muro JG, Bernabé R, Casado A, Balañá C, Sanmartín O, Menéndez MD, Escudero P, Cruz J, Belyakova E, Menéndez D, Buesa JM: Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma; 2005;9(3-4):127-32
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS).
  • BACKGROUND: Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients with advanced soft tissue sarcoma (STS) pretreated with DXR.
  • PATIENTS AND METHODS: Patients with measurable and progressive STS received PLD at 35 mg/(2) every 3 weeks.
  • CONCLUSIONS: PLD did not induce objective remissions in 22 STS patients pretreated with DXR, but progression-free rate figures support the use of this agent in patients who have not progressed under a DXR-containing regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521419.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395634
  •  go-up   go-down


74. Imai S, Ito Y, Ishida T, Hirai T, Ito I, Maekawa K, Takakura S, Iinuma Y, Ichiyama S, Mishima M, Kansai Community Acquired Pneumococcal Pneumonia Study Group: High prevalence of multidrug-resistant Pneumococcal molecular epidemiology network clones among Streptococcus pneumoniae isolates from adult patients with community-acquired pneumonia in Japan. Clin Microbiol Infect; 2009 Nov;15(11):1039-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of multidrug-resistant Pneumococcal molecular epidemiology network clones among Streptococcus pneumoniae isolates from adult patients with community-acquired pneumonia in Japan.
  • MLST analysis identified 49 sequence types (STs), of which 19 were novel. eBURST analysis using the MLST database (3773 STs) grouped the isolates into 27 clonal complexes and three singletons.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bacterial Typing Techniques. Cluster Analysis. DNA Fingerprinting. DNA, Bacterial / chemistry. DNA, Bacterial / genetics. Female. Genotype. Humans. Japan / epidemiology. Male. Microbial Sensitivity Tests. Middle Aged. Molecular Epidemiology. Prevalence. Sequence Analysis, DNA. Serotyping

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694764.001).
  • [ISSN] 1469-0691
  • [Journal-full-title] Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • [ISO-abbreviation] Clin. Microbiol. Infect.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Bacterial
  • [Investigator] Ishida T; Tomii K; Gohma I; Tomioka H; Hayashi M; Kagioka H; Hirabayashi M; Onaru K; Maniwa K; Ito Y; Hirai T; Mishima M; Ito I
  •  go-up   go-down


75. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M, Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. Cancer; 2008 Mar 15;112(6):1197-205
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review.
  • A systematic review was performed to determine whether first-line dose-intensive chemotherapy supported by growth factor or autologous bone marrow/stem cell transplantation improves response rate, time-to-disease progression, or survival compared with standard-dose chemotherapy in patients with inoperable, locally advanced, or metastatic soft tissue sarcoma.
  • On the basis of the available evidence, high-dose chemotherapy with growth factor or autologous bone marrow/stem cell transplantation should not be used in the routine treatment of patients with inoperable, locally advanced, or metastatic soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Growth Substances / administration & dosage. Sarcoma / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18224666.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances
  • [Number-of-references] 35
  •  go-up   go-down


76. Braga LC, Carvalho LR, Binder MC: [Working conditions and common mental disorders among primary health care workers from Botucatu, São Paulo State]. Cien Saude Colet; 2010 Jun;15 Suppl 1:1585-96
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Brazil. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20640320.001).
  • [ISSN] 1678-4561
  • [Journal-full-title] Ciência & saúde coletiva
  • [ISO-abbreviation] Cien Saude Colet
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


77. Hashemi J, Chandrashekar N, Slauterbeck J: The mechanical properties of the human patellar tendon are correlated to its mass density and are independent of sex. Clin Biomech (Bristol, Avon); 2005 Jul;20(6):645-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the effects of donor sex and tissue mass density on the mechanical properties of the patellar tendon have not been established.
  • METHODS: Uniaxial tension tests were performed to determine the effects of donor sex and mass density of the tissue on the mechanical properties of twenty unpaired human patellar tendons (10 male and 10 female; age, 17-50).
  • [MeSH-minor] Adolescent. Adult. Elasticity. Female. Humans. Male. Middle Aged. Patella. Sex Factors. Tensile Strength

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15927738.001).
  • [ISSN] 0268-0033
  • [Journal-full-title] Clinical biomechanics (Bristol, Avon)
  • [ISO-abbreviation] Clin Biomech (Bristol, Avon)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


78. O'Donnell D, Armbruster P: Inbreeding depression affects life-history traits but not infection by Plasmodium gallinaceum in the Asian tiger mosquito, Aedes albopictus. Infect Genet Evol; 2010 Jul;10(5):669-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore created replicate inbred (two generations of full-sib mating, expected f=0.375) and control (expected f approximately 0.07) lines of Ae. albopictus and measured life-history traits including larval survivorship, adult longevity, and female wing length (body size) as well as susceptibility to infection by a model pathogen, Plasmodium gallinaceum.
  • Inbred mosquitoes had significantly reduced larval survivorship and female adult longevity but inbreeding did not affect male adult longevity or female wing length (body size).
  • Therefore, while our results did not support the hypothesis that reduced genetic variation influences susceptibility to pathogen infection in this system, we did find evidence for an effect of reduced genetic variation on female adult longevity, an important component of vectorial capacity.

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20359551.001).
  • [ISSN] 1567-7257
  • [Journal-full-title] Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • [ISO-abbreviation] Infect. Genet. Evol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


79. Jin R, Furnary AP, Fine SC, Blackstone EH, Grunkemeier GL: Using Society of Thoracic Surgeons risk models for risk-adjusting cardiac surgery results. Ann Thorac Surg; 2010 Mar;89(3):677-82
MedlinePlus Health Information. consumer health - Heart Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Society of Thoracic Surgeons National Adult Cardiac Surgery Database (STS NCD) has become the national benchmark for cardiac surgery reporting.
  • Several important aspects of its risk-adjustment reporting are discussed, with special emphasis on using the reported individual STS risk scores for analysis and evaluation:.
  • (1) Different risk models are used in different STS NCD versions. (2) STS calibrates risk scores annually to make the annual predicted rates equal the observed rates. (3) The risk scores given by the STS, whether in the approved STS data collection software programs, published risk models, or online calculator, are not calibrated. (4) The end-user is required to calibrate the STS risk scores before using them. (5) After calibration, the STS predicted risk for any given patient is usually smaller, sometimes less than half of the uncalibrated value. (6) STS uses an observed/expected ratio method to calibrate the risk scores; for technical reasons, it is preferable to use an odds ratio method.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20172107.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


80. Hossain A, McDuffie HH, Bickis MG, Pahwa P, Cross Canada Study of Pesticides and Health Researchers: Case-control study on occupational risk factors for soft-tissue sarcoma. J Occup Environ Med; 2007 Dec;49(12):1386-93
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-control study on occupational risk factors for soft-tissue sarcoma.
  • OBJECTIVE: The main objective of this study was to investigate potential association between development of soft-tissue sarcoma (STS) and occupational exposures related to farming and the agricultural industry in Canada.
  • METHODOLOGY: A population-based case-control study of STS was conducted among Canadian men stratified by province of residence and age group.
  • RESULTS: The following variables were positively associated with the incidence of STS: machinist, chicken farming, pulp and paper industry worker, and apartment complex worker.
  • Mixed farming and exposure to chlorine were negatively associated with STS.
  • CONCLUSION: The higher risk of developing STS may be associated with longest-held job as a machinist, short-term jobs as chicken farm worker, pulp and paper industry worker, and apartment complex worker.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231085.001).
  • [ISSN] 1076-2752
  • [Journal-full-title] Journal of occupational and environmental medicine
  • [ISO-abbreviation] J. Occup. Environ. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Waszak F, Cardoso-Leite P, Gorea A: Perceptual criterion and motor threshold: a signal detection analysis of the relationship between perception and action. Exp Brain Res; 2007 Sep;182(2):179-88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Analysis of Variance. Female. Humans. Male. Perceptual Masking. Photic Stimulation / methods. Psychophysics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 1988 Jun;111 ( Pt 3):643-74 [3382915.001]
  • [Cites] Spat Vis. 1997;10(4):433-6 [9176952.001]
  • [Cites] Nature. 1991 Jan 10;349(6305):154-6 [1986306.001]
  • [Cites] Curr Biol. 1995 Jun 1;5(6):679-85 [7552179.001]
  • [Cites] Trends Cogn Sci. 2001 Sep 1;5(9):369-370 [11520692.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):6275-80 [12719543.001]
  • [Cites] J Exp Psychol Gen. 2000 Dec;129(4):481-507 [11142864.001]
  • [Cites] Vision Res. 2003 Jun;43(12):1337-50 [12742104.001]
  • [Cites] J Neurophysiol. 1990 Mar;63(3):439-46 [2329353.001]
  • [Cites] J Exp Psychol Hum Percept Perform. 1979 Nov;5(4):692-700 [528967.001]
  • [Cites] Percept Psychophys. 2006 Apr;68(3):489-504 [16900839.001]
  • [Cites] Spat Vis. 1997;10(4):437-42 [9176953.001]
  • [Cites] Psychol Sci. 2002 Mar;13(2):112-8 [11933993.001]
  • [Cites] Science. 2001 Apr 20;292(5516):510-2 [11313497.001]
  • [Cites] Trends Cogn Sci. 2001 Nov 1;5(11):457-459 [11684465.001]
  • [Cites] Trends Neurosci. 2000 Nov;23(11):571-9 [11074267.001]
  • (PMID = 17562032.001).
  • [ISSN] 0014-4819
  • [Journal-full-title] Experimental brain research
  • [ISO-abbreviation] Exp Brain Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


82. Medina MJ, Greene CM, Gertz RE, Facklam RR, Jagero G, Hamel M, Shi YP, Slutsker L, Feikin DR, Beall B: Novel antibiotic-resistant pneumococcal strains recovered from the upper respiratory tracts of HIV-infected adults and their children in Kisumu, Kenya. Microb Drug Resist; 2005;11(1):9-17
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multilocus sequence typing (MLST) of 48 PNCNP revealed 33 sequence types (STs), none of which were previously recorded at http://www.mlst.net.
  • Comparisons with all known STs revealed that 23 of these STs were unrelated to other known STs, whereas 10 STs were highly related to STs from internationally disseminated strains, including 2 of the 26 antibiotic-resistant clones recognized by the Pneumococcal Molecular Epidemiology Network.
  • Based upon differing serotypes expressed by strains of identical or closely similar genotypes, there has been an extensive history of capsular switching within seven genetic clusters represented by these 10 STs and related STs described at http://www.mlst.net.
  • [MeSH-minor] Adult. Bacterial Typing Techniques. Carrier State / epidemiology. Carrier State / microbiology. Child. Child, Preschool. Genotype. Humans. Kenya / epidemiology. Nasopharynx / microbiology. Phylogeny

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770088.001).
  • [ISSN] 1076-6294
  • [Journal-full-title] Microbial drug resistance (Larchmont, N.Y.)
  • [ISO-abbreviation] Microb. Drug Resist.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


83. Meadors P, Lamson A, Swanson M, White M, Sira N: Secondary traumatization in pediatric healthcare providers: compassion fatigue, burnout, and secondary traumatic stress. Omega (Westport); 2009-2010;60(2):103-28
MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary aim for this research was to explore the overlap and differences between the concepts related to secondary traumatization: posttraumatic stress disorder (PTSD), secondary traumatic stress (STS), compassion fatigue (CF), and burnout (BRN).
  • A secondary aim for this research was to examine the impact of secondary traumatization and some of the personal and professional elements that affect how pediatric healthcare providers experience PTSD, STS, CF, and BRN.
  • The analyses revealed that a significant overlap existed between the terms of STS, PTSD, BRN, CS, and CF for PICU, NICU, and PEDS providers.
  • Despite previous literature that indicates that the terms STS and CF can be used interchangeably, the two most prominent measures utilized in the assessment of CF and STS are actually capturing at least some unique elements.
  • Given these results, future researchers should examine and conceptualize the difference in etiology, prevalence, symptoms, and treatment efficacy for CF and STS as separate but related entities and then return their focus to understanding secondary traumatization in healthcare providers.
  • [MeSH-minor] Adult. Child. Female. Hospitals, Pediatric / organization & administration. Hospitals, Pediatric / statistics & numerical data. Humans. Intensive Care Units, Pediatric / organization & administration. Male. Middle Aged. Occupational Health. Prevalence. Professional-Patient Relations. United States. Workplace / psychology

  • MedlinePlus Health Information. consumer health - Fatigue.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222232.001).
  • [ISSN] 0030-2228
  • [Journal-full-title] Omega
  • [ISO-abbreviation] Omega (Westport)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Blob LF, Sharoky M, Campbell BJ, Kemper EM, Gilmor MG, VanDenberg CM, Azzaro AJ: Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. CNS Spectr; 2007 Jan;12(1):25-34
Hazardous Substances Data Bank. TYRAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A selegiline transdermal system (STS) was developed to provide antidepressant concentrations of selegiline in the brain, while preserving the gastrointestinal monoamine oxidase A (MAO-A) barrier.
  • The present study was conducted to determine the effect of the STS 6 mg/24 hour on cardiovascular safety following the ingestion of approximately 400 mg of tyramine consumed as a component of aged cheeses.
  • METHODS: In this open-label, single-center phase I study, cardiovascular vital signs were recorded following tyramine challenges during placebo and STS 6 mg/24 hr treatment.
  • RESULTS: Ingestion of tyramine-enriched meals following 13 consecutive days of treatment with the STS 6 mg/24 hr (pharmacokinetic steady-state) produced no clinically significant changes in cardiovascular vital signs in 12 healthy adult male subjects.
  • No evidence of a tyramine pressor effect on systolic blood pressure or evidence of hypertensive crisis occurred during the STS treatment.
  • CONCLUSION: These results suggest that STS 6 mg/24 hr may be administered without concern for dietary tyramine consumption.
  • [MeSH-minor] Administration, Cutaneous. Adolescent. Adult. Double-Blind Method. Drug Interactions. Drug-Related Side Effects and Adverse Reactions. Humans. Male. Middle Aged

  • Hazardous Substances Data Bank. SELEGILINE HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192761.001).
  • [ISSN] 1092-8529
  • [Journal-full-title] CNS spectrums
  • [ISO-abbreviation] CNS Spectr
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Monoamine Oxidase Inhibitors; 2K1V7GP655 / Selegiline; X8ZC7V0OX3 / Tyramine
  •  go-up   go-down


85. Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson RP, Society of Thoracic Surgeons Quality Measurement Task Force: The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. Ann Thorac Surg; 2009 Jul;88(1 Suppl):S2-22
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The first version of The Society of Thoracic Surgeons National Adult Cardiac Surgery Database (STS NCD) was developed nearly 2 decades ago.
  • To adjust for these and other changes, all STS risk models have undergone periodic revisions.
  • This report provides a detailed description of the 2008 STS risk model for coronary artery bypass grafting surgery (CABG).
  • METHODS: The study population consisted of 774,881 isolated CABG procedures performed on adult patients aged 20 to 100 years between January 1, 2002, and December 31, 2006, at 819 STS NCD participating centers.
  • Candidate predictor variables were selected based on their availability in versions 2.35, 2.41, and 2.52.1 of the STS NCD and their presence in (or ability to be mapped to) version 2.61.
  • Potential predictor variables were screened for overall prevalence in the study population, missing data frequency, coding concerns, bivariate relationships with outcomes, and their presence in previous STS or other CABG risk models.
  • CONCLUSIONS: New STS risk models have been developed for CABG mortality and eight other endpoints.
  • [MeSH-minor] Adult. Advisory Committees. Age Factors. Aged. Aged, 80 and over. Cardiac Surgical Procedures / methods. Cardiac Surgical Procedures / mortality. Female. Humans. Male. Middle Aged. Models, Cardiovascular. Postoperative Complications / mortality. Prognosis. Risk Adjustment. Sensitivity and Specificity. Sex Factors. Societies, Medical. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19559822.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


86. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, Lehnert T, Strauss LG, Herfarth C, Büchler MW: Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg; 2005 Feb;241(2):286-94
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.
  • OBJECTIVE: The objective of this study was to evaluate the prognostic significance of preoperative positron emission tomography (PET) using 2-fluoro-2-deoxy-D-glucose (FDG) by calculating the mean standardized uptake values (SUV) in patients with resectable soft tissue sarcomas (STS).
  • SUMMARY AND BACKGROUND DATA: FDG-PET might be used as an adjunctive tool (in addition to biopsy and radiologic tomography) in the preoperative prognostic assessment of resectable STS.
  • METHODS: A total of 74 adult patients with STS underwent preoperative FDG-PET imaging with calculation of the SUV.
  • RESULTS: In 55 cases, STS were completely resected (follow up 40 months): 5-year recurrence-free survival rates in patients with SUV <1.59, 1.59 to <3.6, and > or =3.6 were 66%, 24%, and 11%, respectively (P = 0.0034).
  • CONCLUSION: The semiquantitative FDG uptake, as measured by the mean SUV on preoperative PET images in patients with resectable STS, is a useful prognostic parameter.
  • Therefore, FDG-PET can be used to improve the preoperative prognostic assessment in patients with resectable STS.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / mortality. Soft Tissue Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18 / therapeutic use. Humans. Male. Middle Aged. Multivariate Analysis. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2000;10(2):213-23 [10663750.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):918-24 [9731895.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):380-6 [10714631.001]
  • [Cites] Ann Surg. 2000 May;231(5):655-63 [10767786.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2721-30 [10870054.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26 Suppl A:S21-4 [11130875.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2000 Nov;8(4):915-27 [11149686.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):80-7 [11206230.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):293-9 [11224615.001]
  • [Cites] J Nucl Med. 2001 May;42(5):713-20 [11337565.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1096-103 [11378339.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):379-87 [11786564.001]
  • [Cites] J Orthop Sci. 2002;7(1):33-7 [11819129.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3609-14 [11848531.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):786-92 [11857314.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):512-6 [11870529.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):424-34 [11882765.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):153-64 [11884051.001]
  • [Cites] Cancer. 2002 Apr 25;96(2):83-91 [11954025.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):208-17 [12170026.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1149-54 [12192559.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Oct;29(10):1317-23 [12271413.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4199-208 [12377963.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):619-24 [12409668.001]
  • [Cites] Ann Nucl Med. 2002 Sep;16(6):409-16 [12416580.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1015-24 [12569601.001]
  • [Cites] Q J Nucl Med. 2003 Mar;47(1):8-13 [12714949.001]
  • [Cites] J Nucl Med. 2003 May;44(5):717-24 [12732672.001]
  • [Cites] J Nucl Med. 1980 Jul;21(7):670-5 [7391842.001]
  • [Cites] Cancer. 1991 Feb 15;67(4 Suppl):1261-70 [1991287.001]
  • [Cites] Radiologe. 1993 Sep;33(9):513-9 [8234680.001]
  • [Cites] J Nucl Med. 1996 Sep;37(9):1438-44 [8790188.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):695-9 [9024707.001]
  • [Cites] J Nucl Med. 1997 Nov;38(11):1818-23 [9374364.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1215-20 [9607579.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1773-82 [10673991.001]
  • (PMID = 15650639.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC1356914
  •  go-up   go-down


87. Demura S, Yamada T: Height of chair seat and movement characteristics in sit-to-stand by young and elderly adults. Percept Mot Skills; 2007 Feb;104(1):21-31
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The height of a chair seat affects the burden on the lower limbs during the sit-to-stand (STS).
  • To develop an objective test to evaluate muscle function of the lower limbs using floor reaction force during a STS, the relationship between chair-seat height and the burden on the lower legs must be assessed.
  • To examine the influence of the chair-seat height, floor reaction forces during a STS performed with 5 chair heights adjusted to each subject's lower leg length were compared.
  • The force production and quickness of movement tended to decrease in the phases of trunk flexion and knee and hip joint extension when performing a STS from a lower chair, when the chair height differed by 20% (6.2 cm) from the lower leg length, and was marked when the difference between chair height and lower leg length became larger.
  • In 52 elderly and 50 young adults, floor reaction forces during a STS performed from a chair of the same height as subjects' lower leg lengths were compared.
  • [MeSH-minor] Activities of Daily Living. Adolescent. Adult. Aged. Anthropometry. Biomechanical Phenomena. Humans. Male. Reaction Time / physiology. Weight-Bearing / physiology

  • MedlinePlus Health Information. consumer health - Guide to Good Posture.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450961.001).
  • [ISSN] 0031-5125
  • [Journal-full-title] Perceptual and motor skills
  • [ISO-abbreviation] Percept Mot Skills
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Tesch PA, Berg HE, Bring D, Evans HJ, LeBlanc AD: Effects of 17-day spaceflight on knee extensor muscle function and size. Eur J Appl Physiol; 2005 Jan;93(4):463-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adaptation, Physiological. Adult. Anatomy, Cross-Sectional / methods. Humans. Male. Muscle Contraction. Stress, Mechanical

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Appl Physiol (1985). 2001 Jul;91(1):57-64 [11408413.001]
  • [Cites] Am J Physiol. 1999 Jun;276(6 Pt 2):R1739-48 [10362755.001]
  • [Cites] J Physiol. 2004 Jun 1;557(Pt 2):501-13 [15064323.001]
  • [Cites] J Appl Physiol (1985). 2004 Apr;96(4):1451-8 [14660503.001]
  • [Cites] Exerc Sport Sci Rev. 1990;18:119-66 [2192891.001]
  • [Cites] Aviat Space Environ Med. 1989 Jul;60(7):659-63 [2764849.001]
  • [Cites] J Physiol. 1999 May 1;516 ( Pt 3):915-30 [10200437.001]
  • [Cites] Med Sci Sports Exerc. 2002 Feb;34(2):303-13 [11828241.001]
  • [Cites] Aviat Space Environ Med. 1994 Dec;65(12):1116-21 [7872913.001]
  • [Cites] Acta Physiol Pharmacol Bulg. 2001;26(1-2):21-7 [11693395.001]
  • [Cites] J Appl Physiol (1985). 2000 Dec;89(6):2158-64 [11090562.001]
  • [Cites] J Appl Physiol (1985). 1997 Mar;82(3):807-10 [9074967.001]
  • [Cites] J Appl Physiol (1985). 1997 Jan;82(1):182-8 [9029214.001]
  • [Cites] J Appl Physiol (1985). 1999 Jan;86(1):85-92 [9887117.001]
  • [Cites] J Appl Physiol (1985). 1991 Apr;70(4):1882-5 [2055867.001]
  • [Cites] Physiologist. 1990 Feb;33(1 Suppl):S1-3 [2371310.001]
  • [Cites] J Appl Physiol (1985). 1995 Mar;78(3):976-89 [7775344.001]
  • [Cites] J Appl Physiol (1985). 1992 Nov;73(5):2172-8 [1474100.001]
  • [Cites] Am J Sports Med. 1988 Nov-Dec;16(6):624-9 [3239619.001]
  • [Cites] Aviat Space Environ Med. 1994 Aug;65(8):752-6 [7980338.001]
  • [Cites] Med Sci Sports Exerc. 2000 Oct;32(10):1743-7 [11039647.001]
  • [Cites] J Appl Physiol (1985). 2001 Jun;90(6):2203-11 [11356784.001]
  • [Cites] J Appl Physiol (1985). 1992 Apr;72(4):1493-8 [1534323.001]
  • [Cites] Acta Physiol Scand. 1996 May;157(1):63-70 [8735655.001]
  • [Cites] Aviat Space Environ Med. 1995 Dec;66(12):1151-4 [8747608.001]
  • [Cites] Eur J Appl Physiol. 2004 Dec;93(3):294-305 [15338217.001]
  • [Cites] Med Sci Sports Exerc. 1997 Nov;29(11):1462-8 [9372483.001]
  • [Cites] Eur J Appl Physiol. 2003 Oct;90(3-4):275-82 [13680242.001]
  • [Cites] Arch Phys Med Rehabil. 1988 Dec;69(12):1030-2 [3214261.001]
  • [Cites] Aviat Space Environ Med. 1992 Aug;63(8):678-83 [1510640.001]
  • (PMID = 15517339.001).
  • [ISSN] 1439-6319
  • [Journal-full-title] European journal of applied physiology
  • [ISO-abbreviation] Eur. J. Appl. Physiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Keywords] NASA ; NASA Discipline Musculoskeletal / NASA Experiment Number 284054 / Non-NASA Center
  • [Space-flight-mission] Flight Experiment; STS-78 Shuttle Project; manned; short duration
  • [Investigator] LeBlanc AD
  • [General-notes] NASA/ Grant number: NASA NAS 9-18952.
  •  go-up   go-down


89. Janssen WG, Bussmann JB, Horemans HL, Stam HJ: Validity of accelerometry in assessing the duration of the sit-to-stand movement. Med Biol Eng Comput; 2008 Sep;46(9):879-87
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we assessed the validity of ambulatory accelerometric measurement of the sit-to-stand (STS) movement duration.
  • We compared accelerometric and opto-electronic assessment of the STS movement duration under four conditions (comfortable, slow, fast movement and exaggerated trunk flexion) with six healthy subjects and six subjects with stroke who performed movements six times under each condition.
  • Accelerometric and opto-electronic data of STS movement duration were strongly related (r = 0.98).
  • Our results indicate that accelerometry can provide valid data on the STS movement duration, furthermore during its use additional information on the STS movement, such as balance control, can be recorded.
  • [MeSH-minor] Acceleration. Adult. Aged. Biomechanical Phenomena. Female. Humans. Male. Middle Aged. Reproducibility of Results. Signal Processing, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Guide to Good Posture.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gerontol A Biol Sci Med Sci. 2004 Nov;59(11):1207-12 [15602077.001]
  • [Cites] J Biomech. 2002 Apr;35(4):537-42 [11934425.001]
  • [Cites] Neurorehabil Neural Repair. 2000;14 (3):181-5 [11272474.001]
  • [Cites] Med Sci Sports Exerc. 1990 Jun;22(3):378-84 [2381306.001]
  • [Cites] Phys Ther. 1995 Feb;75(2):105-13; discussion 113-8 [7846131.001]
  • [Cites] Biol Rev Camb Philos Soc. 2006 May;81(2):259-91 [16573844.001]
  • [Cites] Arch Phys Med Rehabil. 1993 Oct;74(10):1095-9 [8215863.001]
  • [Cites] Percept Mot Skills. 1995 Feb;80(1):163-6 [7624188.001]
  • [Cites] J Pediatr. 2001 Dec;139(6):880-6 [11743519.001]
  • [Cites] Res Q Exerc Sport. 1999 Jun;70(2):113-9 [10380242.001]
  • [Cites] Med Biol Eng Comput. 2007 Oct;45(10):969-76 [17653580.001]
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • [Cites] Med Biol Eng Comput. 2005 Mar;43(2):265-72 [15865138.001]
  • [Cites] Clin Rehabil. 1998 Apr;12(2):99-106 [9619651.001]
  • [Cites] Gait Posture. 2005 Oct;22(2):126-31 [16139747.001]
  • [Cites] Arch Phys Med Rehabil. 2004 Jan;85(1):70-6 [14970971.001]
  • [Cites] Scand J Rehabil Med. 1998 Jun;30(2):81-6 [9606769.001]
  • [Cites] J Gerontol. 1991 May;46(3):M91-8 [2030272.001]
  • [Cites] Phys Ther. 2001 Apr;81(4):995-1005 [11276182.001]
  • [Cites] Am J Phys Med Rehabil. 2003 Jan;82(1):42-7 [12510184.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Dec;82(12 ):1650-4 [11733877.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2002 Jul;29(7):527-36 [12060093.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Sep;56(9):M538-47 [11524445.001]
  • [Cites] J Am Geriatr Soc. 1991 Feb;39(2):142-8 [1991946.001]
  • [Cites] Psychophysiology. 1998 Sep;35(5):488-96 [9715093.001]
  • [Cites] Scand J Rehabil Med. 2000 Dec;32(4):187-92 [11201626.001]
  • [Cites] Physiol Meas. 2006 Oct;27(10):999-1008 [16951459.001]
  • [Cites] Arch Phys Med Rehabil. 1998 Sep;79(9):1043-6 [9749681.001]
  • [Cites] Phys Ther. 1990 Oct;70(10):638-48; discussion 648-51 [2217543.001]
  • [Cites] Percept Mot Skills. 2006 Aug;103(1):215-22 [17037663.001]
  • [Cites] Technol Health Care. 1997 Oct;5(4):307-18 [9429271.001]
  • [Cites] Arch Phys Med Rehabil. 1994 Jun;75(6):653-60 [8002764.001]
  • [Cites] Am J Phys Med Rehabil. 2000 Nov-Dec;79(6):519-25 [11083302.001]
  • [Cites] Clin Rehabil. 1998 Dec;12(6):455-64 [9869249.001]
  • [Cites] Age Ageing. 1998 Mar;27(2):137-46 [16296673.001]
  • [Cites] Pain. 1998 Feb;74(2-3):153-61 [9520229.001]
  • [Cites] J Biomech. 2006;39(2):354-8 [16321638.001]
  • [Cites] Neuroscience. 2006;137(2):385-92 [16289889.001]
  • [Cites] Physiol Meas. 2006 Aug;27(8):713-23 [16772670.001]
  • [Cites] J Biomech. 1990;23(11):1123-38 [2277047.001]
  • (PMID = 18626677.001).
  • [ISSN] 1741-0444
  • [Journal-full-title] Medical & biological engineering & computing
  • [ISO-abbreviation] Med Biol Eng Comput
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


90. Issels RD: High-risk soft tissue sarcoma: clinical trial and hyperthermia combined chemotherapy. Int J Hyperthermia; 2006 May;22(3):235-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-risk soft tissue sarcoma: clinical trial and hyperthermia combined chemotherapy.
  • For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival.
  • Systemic chemotherapy has been integrated either after (adjuvant) or before (neoadjuvant) optimal local treatment by surgery and radiotherapy in HR-STS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced / methods. Sarcoma / therapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Combined Modality Therapy / methods. Humans. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754344.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 14
  •  go-up   go-down


91. Benassi MS, Ponticelli F, Azzoni E, Gamberi G, Pazzaglia L, Chiechi A, Conti A, Spessotto P, Scapolan M, Pignotti E, Bacchini P, Picci P: Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas. Histol Histopathol; 2007 09;22(9):1017-24
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
  • In recent years, classification of soft-tissue sarcomas (STS) has improved with cytogenetic analyses, but their clinical behavior is still not easily predictable.
  • Real-time PCR was performed on human STS cell lines and tissues from highly malignant STS, including leiomyosarcomas and malignant fibrous histiocytomas, to evaluate the expression of urokinase-type plasminogen activator (uPA), uPA receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1).
  • In agreement with data on STS cell lines, significant up-regulation for uPA and PAI-1 genes compared to reference values was seen.
  • Clearly, the controversial role of PAI-1 protein requires further biological analyses, but evident involvement of uPA/PAI-1 gene overexpression in STS malignancy may highlight a molecular defect useful in discriminating STS high-risk patients.
  • [MeSH-major] Gene Expression. Plasminogen Activator Inhibitor 1 / metabolism. Sarcoma / metabolism. Urokinase-Type Plasminogen Activator / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cell Culture Techniques. Cell Line, Tumor. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Receptors, Urokinase Plasminogen Activator. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523079.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Plasminogen Activator Inhibitor 1; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


92. Rimol LM, Specht K, Hugdahl K: Controlling for individual differences in fMRI brain activation to tones, syllables, and words. Neuroimage; 2006 Apr 1;30(2):554-62
SciCrunch. NeuroSynth: Data: Activation Foci .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous neuroimaging studies have consistently reported bilateral activation to speech stimuli in the superior temporal gyrus (STG) and have identified an anteroventral stream of speech processing along the superior temporal sulcus (STS).
  • Comparing words > tones and syllables > tones yielded activation in the left posterior MTG and the lateral STG (upper bank of STS).
  • In the right temporal lobe, the activation was located in the MTG/STS (lower bank).
  • Comparing left and right temporal lobe cluster sizes from the words > tones and syllables > tones contrasts on single-subject level demonstrated a statistically significant left lateralization for speech sound processing in the STS/MTG area.
  • [MeSH-minor] Acoustic Stimulation. Adult. Data Interpretation, Statistical. Dichotic Listening Tests. Female. Humans. Image Processing, Computer-Assisted. Individuality. Male. Psychomotor Performance / physiology. Software. Temporal Lobe / physiology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343948.001).
  • [ISSN] 1053-8119
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviation] Neuroimage
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Chenot JF, Simmenroth-Nayda A, Koch A, Fischer T, Scherer M, Emmert B, Stanske B, Kochen MM, Himmel W: Can student tutors act as examiners in an objective structured clinical examination? Med Educ; 2007 Nov;41(11):1032-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Using a checklist and a global rating, teaching doctors (TDs) and student tutors (STs) simultaneously assessed students in basic clinical skills at 4 OSCE stations.
  • The inter-rater agreement between TDs and STs was calculated by kappa values and paired t-tests.
  • Most students felt that assessment by STs would result in the same grades as assessment by TDs (64%) and that it would be similarly objective (69%).
  • CONCLUSIONS: On the basis of our results, STs can act as examiners in summative OSCEs to assess basic medical skills.
  • Students accepted assessment performed by STs.
  • [MeSH-minor] Adult. Attitude of Health Personnel. Humans. Observer Variation. Students, Medical

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17973763.001).
  • [ISSN] 0308-0110
  • [Journal-full-title] Medical education
  • [ISO-abbreviation] Med Educ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Gottfredsson M, Diggle MA, Lawrie DI, Erlensdóttir H, Hardardóttir H, Kristinsson KG, Clarke Sc: Neisseria meningitidis sequence type and risk for death, Iceland. Emerg Infect Dis; 2006 Jul;12(7):1066-73
MedlinePlus Health Information. consumer health - Meningococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the association of patient's age and sex, meningococcal serogroups, and sequence types (STs) with outcomes.
  • Overall, 59 different STs were identified, 19 of which were unique to Iceland.
  • The most common STs were 32 (24.6%), 11 (19.9%), and 10 (10.2%).
  • This study shows evolutionary trends of meningococcal isolates in a relatively isolated community and highlights an association between unique STs and poor outcome.
  • [MeSH-minor] Adolescent. Adult. Aging. Anti-Bacterial Agents / pharmacology. Child. Child, Preschool. Drug Resistance, Bacterial. Female. Humans. Iceland / epidemiology. Infant. Longitudinal Studies. Male. Phylogeny. Risk Factors

  • Genetic Alliance. consumer health - Neisseria meningitidis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Microbiol. 1999 Dec;48(12):1055-64 [10591158.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4649-53 [16145121.001]
  • [Cites] J Clin Microbiol. 2001 Sep;39(9):3066-71 [11526130.001]
  • [Cites] Microb Drug Resist. 2002 Fall;8(3):187-92 [12363007.001]
  • [Cites] J Mol Microbiol Biotechnol. 2002 Nov;4(6):515-7 [12432950.001]
  • [Cites] BMJ. 2003 Sep 13;327(7415):596-7 [12969927.001]
  • [Cites] Clin Infect Dis. 2003 Oct 1;37(7):912-20 [13130402.001]
  • [Cites] Br J Biomed Sci. 2003;60(4):204-9 [14725336.001]
  • [Cites] Bull World Health Organ. 2003;81(10):745-50; discussion 751-5 [14758435.001]
  • [Cites] J Infect Dis. 2004 Mar 1;189(5):785-96 [14976594.001]
  • [Cites] Emerg Infect Dis. 2004 Mar;10(3):526-9 [15109429.001]
  • [Cites] J Med Microbiol. 2004 Jul;53(Pt 7):657-62 [15184538.001]
  • [Cites] Emerg Infect Dis. 2004 Oct;10(10):1812-5 [15504268.001]
  • [Cites] N Engl J Med. 2004 Oct 28;351(18):1849-59 [15509818.001]
  • [Cites] Br Med J (Clin Res Ed). 1982 May 29;284(6329):1618-21 [6805630.001]
  • [Cites] Lancet. 1986 Sep 6;2(8506):555-8 [2875290.001]
  • [Cites] Clin Infect Dis. 1992 Feb;14(2):394-402 [1554823.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3140-5 [9501229.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1263-71 [15776372.001]
  • [Cites] Emerg Infect Dis. 2005 Jun;11(6):977-9 [15963302.001]
  • [Cites] J Infect Dis. 2005 Sep 1;192(5):791-800 [16088828.001]
  • [Cites] JAMA. 2001 Aug 8;286(6):694-9 [11495619.001]
  • (PMID = 16836822.001).
  • [ISSN] 1080-6040
  • [Journal-full-title] Emerging infectious diseases
  • [ISO-abbreviation] Emerging Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC3291058
  •  go-up   go-down


95. Funovics PT, Vaselic S, Panotopoulos J, Kotz RI, Dominkus M: The impact of re-excision of inadequately resected soft tissue sarcomas on surgical therapy, results, and prognosis: A single institution experience with 682 patients. J Surg Oncol; 2010 Nov 1;102(6):626-33
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of re-excision of inadequately resected soft tissue sarcomas on surgical therapy, results, and prognosis: A single institution experience with 682 patients.
  • BACKGROUND AND OBJECTIVES: Due to their rare incidence soft tissue sarcomas (STS) are often resected without clear margins.
  • The aim of this study was to investigate the impact of re-excision of STS on survival.
  • METHODS: Out of 752 patients with STS (406 men and 346 women, average age 51 years), 310 patients were referred after an inadequate resection, 442 patients presented for primary treatment.
  • CONCLUSIONS: An inadequate excision of a STS does not cogently mean deterioration of overall survival but necessitates an ample and quick re-resection.
  • [MeSH-major] Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Retreatment. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886550.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Kujala MV, Tanskanen T, Parkkonen L, Hari R: Facial expressions of pain modulate observer's long-latency responses in superior temporal sulcus. Hum Brain Mapp; 2009 Dec;30(12):3910-23
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cortical activation sequence during observation of the facial expressions of pain advanced from occipital to temporo-occipital areas, and it differed between Provoked and Chronic pain expressions in the right middle superior temporal sulcus (STS) at 300-500 ms: the responses were about a third stronger for Provoked than Chronic pain faces.
  • Furthermore, the responses to Provoked pain faces were about 40% stronger in the right than the left STS, and they decreased from the first to the second measurement session by one-fourth, whereas no similar decrease in responses was found for Chronic pain faces.
  • Thus, the STS responses to the pain expressions were modulated by the intensity of the observed pain and by stimulus repetition; the location and latency of the responses suggest close similarities between processing of pain and other affective facial expressions.
  • [MeSH-minor] Adult. Emotions / physiology. Humans. Magnetoencephalography. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19479731.001).
  • [ISSN] 1097-0193
  • [Journal-full-title] Human brain mapping
  • [ISO-abbreviation] Hum Brain Mapp
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Seleznev K, Zhao C, Zhang XH, Song K, Ma ZA: Calcium-independent phospholipase A2 localizes in and protects mitochondria during apoptotic induction by staurosporine. J Biol Chem; 2006 Aug 4;281(31):22275-88
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we investigate whether group VIA Ca2+-independent PLA2 (iPLA2) plays a role in the protection of mitochondrial function from damage caused by mitochondrially generated ROS during apoptotic induction by staurosporine (STS).
  • We show that iPLA2-expressing cells were relatively resistant to STS-induced apoptosis. iPLA2 localized to mitochondria even before apoptotic induction, and most iPLA2-associated mitochondria were intact in apoptotic resistant cells.
  • Inhibition of caspase 8 has little effect on STS-induced apoptosis in INS-1 cells.
  • Finally, we found that STS down-regulated endogenous iPLA2 transcription in both INS-1 and iPLA2-expressing INS-1 cells without affecting the expression of group IV Ca2+-dependent PLA2.
  • Down-regulation of endogenous iPLA2 by STS may result in the loss of mitochondrial membrane repair functions and lead to mitochondrial failure and apoptosis.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7148-54 [11585748.001]
  • [Cites] FEBS Lett. 2001 Dec 14;509(3):435-8 [11749969.001]
  • [Cites] Biochem J. 2002 Feb 15;362(Pt 1):23-32 [11829736.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1259-63 [11818574.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):423-32 [11864614.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Apr;282(4):E820-33 [11882502.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12001-8 [11812781.001]
  • [Cites] FEBS Lett. 2002 Jul 31;524(1-3):25-30 [12135736.001]
  • [Cites] Cell. 1997 Apr 18;89(2):175-84 [9108473.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11118-27 [9111008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5073-7 [9144192.001]
  • [Cites] J Neurosci Res. 1998 Feb 1;51(3):293-308 [9486765.001]
  • [Cites] J Biol Chem. 1998 May 8;273(19):11401-4 [9565547.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13870-7 [9593733.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):16589-94 [9632731.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8786-803 [12483532.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2236-47 [12700660.001]
  • [Cites] FEBS Lett. 2003 Apr 24;541(1-3):1-5 [12706809.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):22231-6 [12719436.001]
  • [Cites] Cell. 2003 Jun 13;113(6):717-30 [12809603.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4459-68 [12881702.001]
  • [Cites] Mol Cell Biochem. 2003 Aug;250(1-2):131-7 [12962151.001]
  • [Cites] Cell Death Differ. 2003 Nov;10(11):1253-9 [14576777.001]
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:269-90 [10611963.001]
  • [Cites] Prog Lipid Res. 2000 May;39(3):257-88 [10799718.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18248-58 [10747887.001]
  • [Cites] Cell. 2000 Jul 7;102(1):33-42 [10929711.001]
  • [Cites] Oncogene. 2000 Sep 21;19(40):4563-73 [11030145.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 31;1488(1-2):1-19 [11080672.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 31;1488(1-2):28-39 [11080674.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1378-87 [11222383.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13198-208 [11278673.001]
  • [Cites] Free Radic Biol Med. 2001 May 15;30(10):1067-77 [11369496.001]
  • [Cites] Exp Neurol. 2001 Sep;171(1):84-97 [11520123.001]
  • [Cites] Lipids. 2001 Jul;36(7):689-700 [11521967.001]
  • [Cites] Free Radic Biol Med. 2003 Dec 1;35(11):1500-14 [14642398.001]
  • [Cites] FASEB J. 2003 Dec;17(15):2202-8 [14656982.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51380-5 [14551214.001]
  • [Cites] Biochemistry. 2004 Feb 3;43(4):918-30 [14744135.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):113-20 [14730314.001]
  • [Cites] Antioxid Redox Signal. 2004 Apr;6(2):209-25 [15025923.001]
  • [Cites] Biochem Cell Biol. 2004 Feb;82(1):99-112 [15052331.001]
  • [Cites] Mol Aspects Med. 2004 Feb-Apr;25(1-2):17-26 [15051313.001]
  • [Cites] Chem Phys Lipids. 2004 May;129(2):133-60 [15081856.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):19-23 [15093244.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1011:177-84 [15126295.001]
  • [Cites] Mol Cell. 2004 May 7;14(3):277-87 [15125832.001]
  • [Cites] J Biol Chem. 2004 Jun 11;279(24):25219-25 [15070903.001]
  • [Cites] Annu Rev Biochem. 2004;73:87-106 [15189137.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):40385-91 [15252038.001]
  • [Cites] Annu Rev Nutr. 1985;5:365-90 [2992549.001]
  • [Cites] J Histochem Cytochem. 1986 Sep;34(9):1109-15 [2426339.001]
  • [Cites] J Free Radic Biol Med. 1985;1(5-6):421-7 [3837805.001]
  • [Cites] Biochim Biophys Acta. 1986 Dec 5;879(3):399-409 [3535899.001]
  • [Cites] Trends Pharmacol Sci. 1989 Jun;10(6):218-20 [2672462.001]
  • [Cites] J Leukoc Biol. 1990 May;47(5):440-8 [2159514.001]
  • [Cites] Biochem J. 1990 Dec 15;272(3):589-95 [2268287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8527-31 [7667324.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1129-32 [9027314.001]
  • [Cites] J Lipid Res. 1998 Aug;39(8):1529-42 [9717713.001]
  • [Cites] Cell. 1998 Aug 21;94(4):481-90 [9727491.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27084-90 [9765224.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):441-6 [9989411.001]
  • [Cites] J Lipid Res. 1999 Oct;40(10):1837-45 [10508203.001]
  • [Cites] Free Radic Biol Med. 2004 Dec 15;37(12):1963-85 [15544916.001]
  • [Cites] Mol Endocrinol. 2005 Feb;19(2):504-15 [15471944.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):188-9 [16408030.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):223-32 [16408039.001]
  • [Cites] J Cell Sci. 2006 Mar 15;119(Pt 6):1005-15 [16492706.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 31;1488(1-2):167-81 [11080686.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;67:1-33 [11525380.001]
  • (PMID = 16728389.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK063076
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 11062-77-4 / Superoxides; EC 3.1.1.- / Phospholipases A; EC 3.1.1.4 / Group VI Phospholipases A2; EC 3.1.1.4 / Phospholipases A2; EC 3.4.22.- / Caspases; H88EPA0A3N / Staurosporine
  • [Other-IDs] NLM/ NIHMS17294; NLM/ PMC1829309
  •  go-up   go-down


98. Woon DT, Serpell JW: Preoperative core biopsy of soft tissue tumours facilitates their surgical management: a 10-year update. ANZ J Surg; 2008 Nov;78(11):977-81
MedlinePlus Health Information. consumer health - Biopsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative core biopsy of soft tissue tumours facilitates their surgical management: a 10-year update.
  • BACKGROUND: Soft tissue sarcomas (STS) are rare.
  • More often than not, the possibility of STS is not considered preoperatively and the lesions are enucleated.
  • The aims of the study were (i) to assess the current accuracy of core biopsy in the diagnosis of STS;.
  • (ii) to assess whether preoperative core biopsy facilitates the surgical management of soft tissue tumours; and (iii) to evaluate whether there has been an increase in the use of core biopsy before referral.
  • METHODS: Patients with soft tissue tumours managed by a surgeon with a special interest in soft STS from 1994 to 2007 were reviewed from data collected in a database prospectively.
  • The accuracy of core biopsy in the diagnosis of soft tissue tumours and planning of definitive surgery were assessed.
  • The overall sensitivity of core biopsy in diagnosing soft tissue tumours was 83.6%.
  • It has a sensitivity of 91.3% and specificity of 100% for malignant STS.
  • CONCLUSIONS: Core biopsy is accurate in the diagnosis of soft tissue tumours.
  • [MeSH-major] Biopsy / methods. Preoperative Care / methods. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Reproducibility of Results. Retrospective Studies. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ANZ J Surg. 2009 May;79(5):407; author reply 407-8 [19566534.001]
  • [CommentIn] ANZ J Surg. 2008 Nov;78(11):945-6 [18959690.001]
  • (PMID = 18959696.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


99. Wente MN, Schwarzbach MH, Hinz U, Leowardi C, Mechtersheimer G, Krempien R, Egerer G, Friess H, Büchler MW: Perioperative outcome in sarcoma surgery. Langenbecks Arch Surg; 2007 Jan;392(1):83-93
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative outcome in sarcoma surgery.
  • INTRODUCTION: Soft tissue sarcomas (STS) are rare tumors accounting for less than 1% of all malignancies.
  • Although disease-specific surgical management is increasingly important, only few data are available for STS.
  • METHODS: Prospectively gathered data of all adult patients undergoing surgery for STS including gastrointestinal stroma tumors (GIST) between October 2001 and October 2004.
  • Statistical analysis was performed using SAS(R) software and patient's data from a computerized sarcoma registry.
  • Recurrence was treated in more than half of the patients with RET STS, and in almost one third of the EXT lesions, while primary occurrence dominated in the VIS.
  • CONCLUSION: STS surgery of a single surgical unit contains predominantly VIS, RET, and EXT tumors.
  • The STS subtype varies with location, as does length of operation, blood loss, morbidity, mortality, and reoperation rate.
  • These data are helpful for planning the perioperative management of adult patients with STS and can be used for prognostic analyses.
  • [MeSH-major] Retroperitoneal Neoplasms / surgery. Sarcoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytogenet Cell Genet. 2000;90(1-2):86-92 [11060455.001]
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Ann Thorac Surg. 2002 Jun;73(6):1704-9 [12078756.001]
  • [Cites] Chirurg. 2000 Jul;71(7):787-94 [10986600.001]
  • [Cites] Hum Pathol. 2002 May;33(5):466-77 [12094371.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):860-9; discussion 869-70 [12796583.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):718-25; discussion 725-7 [15249403.001]
  • [Cites] Ann Surg. 2002 Feb;235(2):217-25 [11807361.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Chirurg. 2000 Nov;71(11):1359-64 [11132322.001]
  • [Cites] J Vasc Surg. 2005 Jul;42(1):88-97 [16012457.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2000 Nov;8(4):915-27 [11149686.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Cancer. 2001 May 15;91(10):1914-26 [11346874.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1996;113:214-7 [9101835.001]
  • [Cites] Radiologe. 1993 Sep;33(9):513-9 [8234680.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):286-94 [15650639.001]
  • [Cites] J Am Coll Surg. 2001 Oct;193(4):373-9 [11584964.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Surgery. 1987 Sep;102(3):447-52 [3629473.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):380-6 [10714631.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):1898-902 [14696429.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):634-9 [15917417.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Pathologe. 2003 May;24(3):182-91 [12739051.001]
  • [Cites] Chirurg. 1993 Jul;64(7):527-34 [8375202.001]
  • [Cites] Chirurg. 2001 Feb;72(2):138-48 [11253672.001]
  • [Cites] Cancer Control. 2005 Jan-Feb;12(1):44-56 [15668652.001]
  • [Cites] Chirurg. 1996 Dec;67(12):1237-43 [9081786.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Eur J Surg Oncol. 2003 Jun;29(5):440-5 [12798748.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):321-4 [8892454.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):1005-22 [7226034.001]
  • [Cites] Dis Colon Rectum. 2002 Mar;45(3):316-21 [12068187.001]
  • [Cites] Hum Pathol. 2002 May;33(5):478-83 [12094372.001]
  • [Cites] J Am Coll Surg. 2002 Apr;194(4):436-47 [11949749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):94-9 [11516857.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):290-9 [11352301.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):617-22 [8631407.001]
  • [Cites] Ann Surg. 1984 Aug;200(2):200-4 [6465975.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1312-5 [9931868.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4344-52 [12409334.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6798-805 [15286712.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2087-93 [10070316.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):189-97 [7842288.001]
  • (PMID = 17131156.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


100. Chenal C, Legue F, Nourgalieva K: Delayed effects of low level acute irradiation and chronic environmental radioactive contamination on DNA lymphocytes of people living in Dolon, a settlement located in the vicinity of the Semipalatinsk nuclear test site (Kazakhstan). Sci Total Environ; 2006 Oct 1;369(1-3):91-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During 42 years several hundred nuclear tests were performed by the former USSR at the Semipalatinsk Test Site (STS, Kazakhstan), of which more than 100 were done in the atmosphere.
  • We report here the late genetic damage of external exposure to radiation and environmental radioactive contamination in people living in Dolon, a small settlement situated in the vicinity of the STS.
  • The comet assay was applied on DNA lymphocytes of 20 exposed women and 32 non-exposed women living at 500 km from the STS.
  • [MeSH-minor] Adult. Comet Assay. Female. Humans. Kazakhstan. Middle Aged. Nuclear Warfare

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16797057.001).
  • [ISSN] 0048-9697
  • [Journal-full-title] The Science of the total environment
  • [ISO-abbreviation] Sci. Total Environ.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radioactive Fallout
  •  go-up   go-down






Advertisement